

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Protocol for The SAFEST Review: The Shock-Absorbing Flooring Effectiveness Systematic Review including older adults and staff in care settings

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-032315
Article Type:	Protocol
Date Submitted by the Author:	12-Jun-2019
Complete List of Authors:	Drahota, Amy; University of Portsmouth, School of Health Sciences & Social Work Felix, Lambert; University of Portsmouth, School of Health Sciences & Social Work Keenan, Bethany; Cardiff University, School of Engineering Lachance, Chantelle; University of Portsmouth, School of Health Sciences & Social Work Laing , Andrew Laing ; University of Waterloo Mackey, Dawn ; Simon Fraser University Raftery, James; University of Southampton, Wessex Institute
Keywords:	Floors and Floorcoverings, Accidental Falls, Wounds and Injuries, Hospitals, Residential Facilities

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 **Protocol for The SAFEST Review: The Shock-Absorbing Flooring**
5 **Effectiveness SysTematic Review including older adults and staff in care**
6 **settings**
7

8 PROSPERO registration number: CRD42019118834
9

10 **Corresponding Author**
11

12
13 Amy Drahota, <http://orcid.org/0000-0001-9772-0220>

14 Principal Research Fellow,

15 School of Health Sciences & Social Work,

16 University of Portsmouth,

17 James Watson West,

18 2 King Richard 1st Rd, Portsmouth, Hampshire,

19 PO1 2FR, UK

20 Telephone: +44 (0)23 92 84 4432

21 Email: amy.drahota@port.ac.uk
22
23
24
25

26 **Co-authors**

27 1. Lambert M Felix, <http://orcid.org/0000-0001-6517-9089>

28 Email: lambert.felix@port.ac.uk

29 School of Health Sciences & Social Work, University of Portsmouth, Portsmouth, UK
30
31

32 2. Bethany Keenan, <https://orcid.org/0000-0001-7787-2892>

33 Email: KeenanB@cardiff.ac.uk

34 School of Engineering, University of Cardiff, Cardiff, UK
35
36

37 3. Chantelle C Lachance, <http://orcid.org/0000-0001-5755-5160>

38 Email: chantelle.lachance@port.ac.uk

39 School of Health Sciences & Social Work, University of Portsmouth, Portsmouth, UK
40
41

42 4. Andrew C Laing, <https://orcid.org/0000-0001-8128-011X>

43 Email: actlaing@uwaterloo.ca

44 University of Waterloo, Canada
45
46

47 5. Dawn C Mackey, <http://orcid.org/0000-0001-9854-1486>

48 Email: dmackey@sfu.ca

49 Simon Fraser University, Canada
50
51

52 6. James Raftery,

53 Email: J.P.Raftery@soton.ac.uk

54 Wessex Institute, University of Southampton, Southampton, UK
55
56

57 Word count: 4000

58 Key words: Floors and Floorcoverings; Accidental Falls; Wounds and Injuries; Hospitals;
59 Residential Facilities.
60

ABSTRACT

Introduction: Falls in hospitals and care homes are a major issue of international concern. Inpatient falls are the most commonly reported safety incident in the United Kingdom's National Health Service (NHS), costing the NHS £630 million a year. Injurious falls are particularly life-limiting and costly. There is a growing body of evidence on shock-absorbing flooring for fall-related injury prevention; however, no systematic review exists to inform practice.

Methods and analysis: We will systematically identify, appraise, and summarise studies investigating the clinical and cost-effectiveness, and experiences of shock-absorbing flooring in hospitals and care homes. Our search will build on an extensive search conducted by a scoping review (inception to May 2016). We will search electronic databases (May 2016 – present), trial registries, and grey literature. We will screen reference lists, conduct forward citation searches, and liaise with study researchers. We will evaluate the influence of floors on fall-related injuries, falls, and staff work-related injuries through randomised and non-randomised studies, consider economic and qualitative evidence, and implementation factors. We will consider risk of bias, assess heterogeneity, and explore potential effect modifiers via subgroup analyses and sensitivity analyses. Where appropriate we will combine studies through meta-analysis. We will use the GRADE approach to evaluate the quality of evidence and present the results using summary of findings tables, and adhere to the PRISMA reporting guidelines.

Ethics and dissemination: We will follow the ethical principles of systematic review conduct, by attending to publication ethics, transparency, and rigour. Our dissemination plan includes peer-reviewed publication, presentations, press release, stakeholder symposium, patient video, and targeted knowledge-to-action reports. This review will inform decision-making around falls management in care settings and identify important directions for future research.

Funding and registration: The systematic review is funded by the NIHR HTA Programme (Project ref 17/148/11), and registered in PROSPERO ([CRD42019118834](https://doi.org/10.1136/2017021188)).

ARTICLE SUMMARY

Strengths and limitations of this study

- This will be a mixed methods systematic review including randomised and non-randomised studies, economic and qualitative evidence;

- Studies will be assessed using the updated Cochrane risk of bias tools for quantitative evidence, and Joanna Briggs Institute method for qualitative studies;
- The quality of the evidence will be summarised using the GRADE approach, with the strength of the review's findings limited to the quantity and internal validity of the included studies;
- Analyses will be at the study level, which limits the scope for exploring moderating factors related to patient-level characteristics on the effectiveness of flooring interventions.
- We will be guided by the Knowledge-to-Action Framework to facilitate the translation of the findings into practice.

INTRODUCTION

Older adults, individuals living with frailty, and individuals with multiple morbidities are at greater risk of falls and fall-related injuries (1, 2). Falls in healthcare settings are a global concern (3). In the United Kingdom (UK), inpatient falls are the most commonly reported safety incident with over 250,000 reported per year in the National Health Service (NHS) in England alone. Of these falls, about 30% result in injury, causing a significant burden for individuals, carers, and healthcare resources due to the costs of continued and additional care and litigation (2). It is estimated that falls in hospitals cost the NHS about £630 million per year (2) which will be higher still if falls in other care settings (e.g. care homes) are included (4), and the wider impacts to the health and social care system are considered (5-6). Falls have a complex aetiology of intrinsic and extrinsic risk factors and no single solution effectively prevents them (3). It is proposed that 25-30% of inpatient falls are preventable, and the prevention of severe falls is a priority (2). A Cochrane review on hip protectors for hip fractures revealed that compliance with this intervention was poor and was a barrier to their use (7). Unlike hip protectors, manipulating the physical environment of care settings is a promising intervention for reducing injurious falls as it requires no compliance from patients or staff, and can accommodate the fact that injuries occur not just to the hip (8). Moreover, both The National Institute for Health and Care Excellence (NICE) Guideline (9), and the National Hip Fracture Database annual report (10) have highlighted the pressing need to investigate environmental adaptations to prevent falls and injuries.

Shock-absorbing flooring systems can reduce the impact forces of falls by decreasing the stiffness of the ground surface (11). However, softer floors could have a negative impact on older individuals' gait, particularly if they have complex health needs, potentially leading to increased falls risk (11-15). The potential benefits and risks of shock-absorbing floors may vary depending on the type of patient utilising them. Further adverse effects of shock-absorbing floors may present in staff if greater effort is required to manoeuvre rolling equipment, potentially increasing the risk of injuries (16).

There has been no comprehensive systematic review focussing on flooring interventions in healthcare settings for fall-related injury prevention. A recent scoping review of flooring interventions involved a thorough search of the literature through May 2016; however, it did not involve a critical appraisal or systematic synthesis (17). A systematic review of studies identified in the scoping review (16,18-25) as well as more recent studies (26-31), will provide a more reliable basis for decision-making and identify the next steps for research.

This publication is an abridged version of the full protocol available on the Health Technology Assessment website (32), and is registered on PROSPERO ([CRD42019118834](https://doi.org/10.1136/201902118834)) (33). Any important protocol amendments will be published via these sites. We have conformed to the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) (34) in the writing of this protocol (supplementary file 1).

Aims and Objectives

We aim to systematically review the evidence on shock-absorbing flooring use in care settings (hospitals and care homes) for fall-related injury prevention in older adults. Specifically, we will:

1. Assess the potential benefits (fall-related injury prevention) and risks (falls; staff injuries) of different flooring systems in care settings.
2. Assess the extent to which these potential benefits and risks may be modified by different study/setting, intervention, and participant characteristics.
3. Critically appraise and summarise current evidence on the resource use, costs and cost-effectiveness of shock-absorbing flooring in care settings for older adults, compared with standard flooring.
4. Summarise findings on the implementation of flooring interventions in the included studies.
5. Summarise the views and experiences of shock-absorbing flooring use from patients'/residents', staff, and visitors' perspectives.
6. Identify gaps in existing evidence.

METHODS

Eligibility criteria

Population

Our main population of interest is older adults in care settings. We have no set cut-off criteria for age, as chronological age may not be a good indicator of frailty (35). Studies must focus on adult populations to be included. We will exclude studies focussing solely on children.

Setting

Studies must have been conducted in a care setting (defined below) including hospitals (acute, sub-acute), intermediate and long-term care settings (nursing and care homes). Studies

1
2
3 conducted in people's own homes, or other settings (e.g. playgrounds, sporting venues) will
4 be excluded.
5
6
7

8 Care settings will be broadly defined as (36):

- 9
10
- 11 ● Care home environments (a facility that provides: communal living facilities for long-term
12 care; overnight accommodation; nursing or personal care; for people with illness, disability
13 or dependence).
 - 14 ● Hospital environments (a facility that provides: communal care where there is an
15 expectation that this care is time limited; overnight accommodation; nursing and personal
16 care for people with illness and disability).
17
18
- 19

20 Interventions

21
22 Interventions may include flooring systems which have been purposely designed to prevent
23 fall-related injuries (e.g. SmartCells, Sorbashock, Kradal), thick vinyl (>5mm thick; e.g. sports
24 floors, such as Tarkett Omnisports Excel), carpet with or without underlay, and other
25 combination flooring systems (e.g. vinyl overlays with padded underlays, such as foam or
26 rubber, or wooden subfloors). Alternative terminology for the intervention may include
27 variations on the terms: compliant flooring, safety flooring, soft flooring, impact absorbing
28 flooring, energy absorbing flooring, low-impact flooring, dual stiffness flooring, low stiffness
29 flooring, absorptive surfaces, cushioned flooring, rubber flooring, acoustic flooring, and carpet.
30
31
32
33
34
35

36 We will exclude studies reporting exclusively on mats as they are not permanently affixed to
37 the floor and do not provide universal coverage or protection. We will exclude studies in which
38 flooring is one component of a package of interventions and the effects of the floor cannot be
39 disentangled from concurrent interventions.
40
41
42
43

44 Comparator

45 Our main comparison group is standard or rigid flooring (e.g. concrete, ≤ 2 mm vinyl/resilient
46 flooring). We will include head-to-head comparisons of different types of shock-absorbing
47 flooring systems where possible.
48
49
50

51 Outcomes

52 The reporting of specific outcomes does not form part of our eligibility criteria.
53
54
55

56 Study Design

57 We will include randomised, non-randomised, observational, economic, and qualitative
58 studies. Whilst randomised trials of flooring are feasible, the nature and logistics of the
59
60

intervention make observational and opportunistic quasi-experimental designs more practical. We will utilise the tables of study design features presented in the Cochrane Handbook (37) to classify included studies by their component design features. The following study designs will be eligible:

- Individually or cluster randomised controlled trials;
- Quasi experimental studies where allocation is non-random;
- Interrupted times series;
- Controlled before and after studies;
- Cohort studies;
- Case-control studies;
- Partial and full economic evaluations, based on a single study or model;
- Qualitative studies to explore experiences, attitudes, and perceptions towards flooring interventions.

We will exclude simple before and after studies measuring quantitative outcomes, with no evaluation of time trends or concurrent control.

Information sources and search strategy

We will build on the search already conducted in a scoping review (17), which had a search cut-off of May 2016. We will further assess the eligibility of clinical (12, 16, 18-26, 38-46) and cost-effectiveness (11, 21, 26, 40-41, 47-63) records identified in the scoping review. We will conduct our search from May 2016 to present, and will not apply any language restrictions. We will undertake a comprehensive search, as listed in Table 1, including electronic databases, grey literature, hand searches, citation screening, and expert consultation.

SEARCH TYPE	INFORMATION SOURCES
Electronic Databases	AgeLine (EBSCO) CINAHL Complete (EBSCO) MEDLINE (EBSCO) NHS Economic Evaluation Database (Centre for Reviews and Dissemination) Scopus Web of Science (Thomson Reuters)
Grey literature search	Clinical trial registries WHO International Clinical Trials Registry Platform (ICTRP) Theses/dissertations ProQuest Theses and Dissertations Abstracts/conference proceedings Biennial Conference of the Australian and New Zealand Falls Prevention Society Canadian Association on Gerontology Annual Scientific and Educational Meeting

	Gerontological Society of America's Annual Scientific Meeting
	International Society for Posture and Gait Research World Congress
	World Conference of Gerontechnology
	World Congress of the International Association of Gerontology and Geriatrics
	Websites
	Agency for Healthcare Research and Quality (AHRQ)
	Canadian Agency for Drugs and Technologies in Health (CADTH)
	NHS Improvement
	NICE Guidelines
	Open Grey (opengrey.eu)
	Parachute Canada
	The National Institute for Occupational Safety and Health (NIOSH)
	The International Network of Agencies for Health Technology Assessment
	UK Health Technology Assessment
	US Center for Health Design
	WHO Health Evidence Database (HEN)
Hand searching and citation screening	Reference lists
	References of included studies
	Forward citation searching of included studies in Web of Science
	Journal
	Age and Ageing

Table 1: List of information sources

We have refined the search strategy of the scoping review to focus on identifying studies of clinical and cost-effectiveness, and qualitative experiences. We have developed our strategy for MEDLINE (supplementary file 2) based on our eligibility criteria, using a combination of keyword synonyms and controlled vocabulary terms (e.g., MeSH). We will adapt the MEDLINE search for other information sources.

Study Records

Data management

We will import the search records into EndNote™ online, and use Covidence (54) to support duplicate record identification, screening, data collection, and risk of bias assessment processes, identification and resolution of discrepancies, and producing a PRISMA flow diagram (55). We will undertake data analysis in RevMan (56), and create Summary of Findings Tables and Evidence Profiles using GRADE Pro (57-58).

Selection process

We will screen titles, abstracts, and full reports independently in duplicate using an eligibility checklist. We will assess all records included in the clinical and cost-effectiveness sections of the scoping review at the full report stage. From the results of the updated search, we will begin by screening titles, and those that look potentially relevant we will review in abstract form. We will then screen the full texts of records that appear definitely or possibly relevant. We will resolve discrepancies through a third independent arbitrator.

Data collection process

Our theoretical framework of potential effect modifiers (Figure 1) will underpin the data collection process. We will develop and pilot the data collection form with a data collection manual to ensure consistency. Two reviewers will independently undertake data collection and assessment of risk of bias.

Data collection will include the following key components of information:

- Study identification
- Time/duration and geographical place of conduct
- Participant characteristics
- Intervention(s)
- Control(s)
- Outcome data acquisition: Method of falls reporting; Classification system of injuries; Identification of fractures (confirmation of diagnosis/type of fractures included); Identification of adverse effects.
- Setting
- Study design
- Risk of bias
- Outcomes data
- Patient and public involvement in the research
- Follow-up questions for study authors.

Outcomes and prioritization

There is no core outcome set specifically for flooring interventions; however we have considered the common outcome data set for fall injury prevention trials in community-dwelling populations (59) and the international consensus statement for trials on hip protectors (60). Recognising the unique features of our review and through stakeholder engagement (61) and

1
2
3 discussion with our public involvement group, we have prioritised the following outcome
4 measures:
5
6
7

8 Primary outcomes:

- 9 • Injurious falls rate per 1000 patient-bed days;
- 10 • Falls rate per 1000 patient-bed days;
- 11
- 12
- 13

14 Secondary outcomes:

- 15 • Fractures per 1000 patient-bed days;
- 16 • Hip fractures per 1000 patient-bed days
- 17 • Number of fallers
- 18 • Number of fallers with injuries (none, minor, moderate, severe, death)
- 19 • Number of adverse events (e.g. staff injuries as defined by study authors)
- 20 • Number of fractures
- 21 • Number of hip fractures
- 22 • Qualitative outcomes (e.g. staff, patients/residents, visitors attitudes, views, and
- 23 experiences)
- 24 • Economic outcomes (to include assessments of quality-adjusted life years)
- 25 • Process outcomes (e.g. ease of, or problems with, flooring installation)
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36

37 **Risk of bias in individual studies**

38 Risk of bias assessment will be undertaken using the updated Cochrane risk of bias tool (ROB
39 2.0) for randomised trials (62) and the ROBINS-I (Risk Of Bias In Non-randomised Studies of
40 Interventions) tool (63) for other quantitative designs. We will assess the risk of bias at the
41 level of study results. Review authors will not be blinded during risk of bias assessments;
42 however, where they have been involved in co-authoring an included study, assessments will
43 be undertaken by at least two other independent reviewers. Supporting information and
44 justification for judgements (high; low; some concerns) will be recorded for each risk of bias
45 domain. We will follow the guidance to derive overall summary risk of bias judgements for
46 each outcome, which will be used to inform our sensitivity analyses and GRADE assessments
47 (57).
48
49
50
51
52
53
54
55

56 **Data analysis (quantitative studies)**

57 Dealing with missing data
58
59
60

1
2
3 We will seek further information from study authors where required. If missing data are from
4 participant/cluster dropouts, we will conduct analyses based on the available data and include
5 an assessment of the problem as part of our risk of bias judgements.
6
7
8

9 Measures of treatment effect

10 We will report rates of injurious falls, falls, and fractures using incidence rate ratios and 95%
11 confidence intervals (CI). We will use risk ratios (95% CI) to describe number of fallers, number
12 of participants with fall-related injuries, and number of participants with fall-related fractures.
13 Where available we will also report hazard ratios for falls including all falls from recurrent
14 fallers. For non-randomised studies, we will record the unadjusted and adjusted estimates and
15 note the factors adjusted for. Where multiple adjusted estimates are presented, we will extract
16 the estimate highlighted as the primary model by the authors, or where this is unclear, take
17 the model which has adjusted for the most covariates. Where rate ratios or risk ratios are not
18 reported, we will calculate them where feasible (37).
19
20
21
22
23
24
25

26 Where studies present a break-down of the severity of injuries (as ordinal outcome data, e.g.
27 none, mild, moderate, severe, death), we will present these descriptively, and if studies have
28 used similar categorisation systems, using figures where feasible. We will report adverse
29 events to staff as a risk or rate ratio (per 100 working staff-days) where possible, or as the
30 number of events observed during the follow-up period, if no clear denominator is known.
31
32
33
34
35

36 Unit of analysis issues

37 To avoid the issue of double counting, we will link multiple associated publications together.
38 When primary studies include multiple study arms, we will either combine the groups (if logical)
39 or include only one pair-wise comparison (intervention versus control) in any one analysis. In
40 the case of cluster randomised trials we will take clustering into account, and plan to adjust
41 the estimates using an intra-cluster correlation coefficient (ICC) borrowed from another similar
42 study if required (37).
43
44
45
46
47

48 Assessment of reporting bias

49 Where possible, we will produce funnel plots with different plotting symbols to identify
50 subgroups. We will only test for funnel plot asymmetry if there are sufficient data (at least 10
51 studies to be combined), and will use visual inspection of the plots to interpret the findings.
52
53
54
55

56 Data synthesis

57 Should meta-analysis be viable, we will opt to combine studies using a random-effects model,
58 assuming that intervention effects are likely to vary across studies (Figure 1). We will use
59
60

1
2
3 generic inverse variance data type to produce forest plots in RevMan (56). Where evidence
4 exists from randomised and non-randomised studies, we will report the data separately, giving
5 more emphasis to the findings from randomised trials. We will organise non-randomised
6 studies according to whether data collection was prospective or retrospective, and if controls
7 were concurrent or historical. If appropriate, we will combine the data from randomised and
8 non-randomised studies to provide an overall summary effect estimate.
9
10
11
12

13 Assessment of heterogeneity

14
15 We will explore heterogeneity irrespective of whether we decide to pool studies in a meta-
16 analysis. Heterogeneity will be assessed through a combination of visual inspection of the
17 forest plots, along with consideration of tests for homogeneity (Chi^2 with statistical significance
18 set at $P < 0.10$), and measures for inconsistency (I^2) and heterogeneity (τ^2).
19
20
21
22

23
24 Where feasible, we plan to undertake subgroup analysis based on:

- 25 - Study design (randomised, non-randomised);
- 26 - Study setting (hospital, care home);
- 27 - Acuity of care (acute, sub-acute, intermediate, long-term care); and
- 28 - Flooring type (novel shock-absorbing flooring, thick vinyl/vinyl & underlay, carpet, wooden
29 subfloor)

30 Sensitivity analyses

31
32 We will undertake sensitivity analyses based on:

- 33 - Risk of bias (e.g. removing studies at high risk of bias on the ROB2.0 tool, or critical/serious
34 risk of bias on the ROBINS-I tool);
- 35 - Choice of effect estimates (e.g. where multiple adjusted estimates are reported, the
36 analysis will be run on the most optimistic and pessimistic scenarios); and
- 37 - Adjustment for clustering where an ICC has been borrowed from another study (e.g. we will
38 assess the impact of opting for more or less conservative adjustments).
39
40
41
42
43
44
45
46
47
48

49 Synthesis of Qualitative Studies

50
51 We will use a meta-aggregative approach to synthesise data from qualitative studies (64). We
52 will derive generalizable statements, in the form of recommendations that can be used to guide
53 end-users (e.g. NHS Chief Executives, care home managers, estates/facilities managers,
54 healthcare designers and builders, health and social care professionals, patients, residents,
55 and carers). We will critically assess the studies using the Joanna Briggs Institute's critical
56
57
58
59
60

1
2
3 appraisal tool (64). We will follow the data collection process as above, and use QSR NVivo
4 software for data analysis (65).
5
6
7

8 **Synthesis of economic evidence**

9

10 We will align our approach for the incorporation of costs data to an exemplar systematic review
11 by Garrison and colleagues (66). One reviewer (LF) will extract all data from included
12 economic evaluations, which will be checked by an expert reviewer (JR). We will design our
13 data extraction form based on the format and guidelines used to produce structured abstracts
14 of full economic evaluations for inclusion in the NHS Economic Evaluation Database. We will
15 assess the methodological quality of included economic evaluations through the use of
16 recognised checklists based on guidelines for economic submissions to the British Medical
17 Journal (for economic evaluations based on a single study) (67), and for quality assessment
18 in economic decision-analytic models (for model-based economic evaluations) (68). Data
19 extraction will include study characteristics such as country, settings, aims, and
20 methodological aspects related to economic evaluation, individual items within the respective
21 checklists (67-68), and the economic variables. We will collect the following economic
22 variables, if reported: costs of flooring (purchasing, installation, maintenance); costs of falls
23 based on injury, such as hospital resources (e.g. increased length of stay, additional surgery
24 needs), and post-discharge healthcare cost (e.g. hospital readmission, outpatient visits); utility
25 measures such as quality of life, life years and quality adjusted life years; and summary
26 measures such as incremental cost-effectiveness ratio (ICERs), net monetary benefits, and
27 value of information (VoI).
28
29
30
31
32
33
34
35
36
37
38
39

40 We will classify economic evaluations by type (*Partial evaluations*: 'outcome description', 'cost
41 description', 'cost-outcome description', 'efficacy or effectiveness evaluation', or 'cost-
42 analysis'; *Full economic evaluations*: 'cost-effectiveness analysis', 'cost-utility analysis', or
43 'cost-benefit analysis') and as either an economic evaluation based on a single study or a
44 model-based economic evaluation. Where necessary, we will seek additional information from
45 study authors.
46
47
48
49
50

51 We will tabulate and summarise the results narratively in the text. We will adjust all costs to
52 2019 Pound Sterling values using Gross Domestic Product deflators, and use relevant
53 exchange rates for international comparisons.
54
55
56
57
58
59
60

Confidence in Cumulative Evidence

Quantitative Evidence

We will assess the quality of evidence across the included studies at outcome level for each comparison using GRADE (57), and incorporate these assessments into Summary of Findings (SoF) Tables using the GRADEpro software (58). Our main comparison will be 'shock-absorbing flooring versus standard flooring', and we will include separate SoF tables for hospitals and care homes. Supplementary SoF tables will be developed for different types of shock-absorbing floors versus standard flooring, and for head-to-head comparisons of different shock-absorbing flooring interventions.

We will include the following outcomes: 1) injurious falls rate per 1000 patient-bed days; 2) falls rate per 1000 patient-bed days; 3) fractures per 1000 patient bed days; 4) hip fractures per 1000 patient bed days; 5) number of fallers; 6) number of fallers with injuries (none, minor, moderate, severe); and 7) number of adverse events related to staff injuries. We will create 'Evidence profile' and Summary of Findings' tables (57). The GRADE system provides a grade of the overall quality of the evidence for each outcome on one of four levels: high, moderate, low, very low.

Qualitative Evidence

We will follow the CERQual group's recommendations to assess the quality of qualitative evidence included in the review (69). We will assess each review finding based on methodological limitations, coherence, adequacy of data, and relevance (70). We will make an overall assessment of confidence for each review finding on one of the four levels: high, moderate, low, very low. We will create 'CERQual Evidence profile', and 'Summary of Qualitative Findings (SoQF)' tables.

ENGAGEMENT WITH STAKEHOLDERS

We will consult with key stakeholders and a range of potential knowledge users during our review (i.e. small group meetings, one-to-one discussions, videoconferences, teleconferences, and email). Our Advisory Board includes the following knowledge users: Falls in older people NICE Guideline Developer; Safety and Improvement Clinical Lead (Leeds Teaching Hospitals NHS Trust); director/chairman of the Health Estates and Facilities Management Association; chairman of the National Care Association; public members; and shock-absorbing flooring researchers from health sciences and engineering disciplines in the UK and Canada. Collectively, members of the board possess the relevant expertise and decision-making authority to critically evaluate and implement shock-absorbing flooring

1
2
3 systems in high-risk environments such as hospitals and long-term care in the UK, and utilise
4 systematic review evidence to inform future research.
5
6
7

8 An interactive process of communication between researchers and the Advisory Board will be
9 used throughout the review process. We will involve the Board in a number of important ways:
10 (1) in providing input on the design and implementation of the review; (2) as members of the
11 project team who attend project meetings and inform us of emerging primary research
12 evidence; (3) in the interpretation of findings and identification of research gaps; and (4) in the
13 packaging and dissemination of the review's findings in a form that is relevant, practical and
14 easily interpreted by other decision-makers and knowledge users.
15
16
17
18
19

20 **PATIENT AND PUBLIC INVOLVEMENT (PPI)**

21
22
23 Three public members engaged actively in the preparation of our original funding proposal.
24 The members informed our decisions related to the systematic review methodology,
25 particularly prioritising outcomes, confirming settings, and development of the theoretical
26 framework.
27
28
29

30
31 The public members will participate in five specific PPI meetings over the course of the project.
32 Each meeting will include a brief training session to explain the stage of the review the project
33 is at, and the processes and tasks involved. They will contribute to the conduct of the
34 systematic review in the following ways: (1) Commenting on the clarity and
35 comprehensiveness of the protocol; Providing an independent judgement as to the fairness,
36 transparency, and consistency of (2) the risk of bias, and (3) GRADE judgements made by
37 the project team; (4) Providing feedback on the clarity of information presented in the
38 Summary of Findings Tables, as well as the order and presentation of comparisons and
39 subgroups; and (5) Providing feedback on the clarity, comprehensiveness, and presentation
40 of the project outputs (including the Plain English Summary).
41
42
43
44
45
46
47

48 **ETHICS AND DISSEMINATION**

49
50 We do not need to obtain ethical review, as this is an evidence synthesis. Nonetheless, our
51 ethical considerations (71) will relate to: (1) appropriateness of authorship on the final works;
52 (2) avoidance of duplication in the publication of the findings; (3) avoiding plagiarism by
53 ensuring that all reported findings are sufficiently cited and attributable to the source material;
54 (4) transparency, in the form of acknowledging all contributions and competing interests ; (5)
55 having due rigour in the data collection and reporting phases of the review to ensure the
56
57
58
59
60

1
2
3 accuracy of the findings; and (6) flagging suspected fraudulent or plagiarised research to the
4 publishing journals.
5
6

7 Our research approach is underpinned by the Knowledge to Action Framework (72), and will
8 ensure involvement of knowledge users with researchers throughout the process.
9

10 We will disseminate our research outputs using the following media:

- 11 • Open access peer-reviewed journal publication;
- 12 • Presentations at national and international conferences, and a webinar;
- 13 • Press release/social media with an item in relevant media outlets (e.g. The
14 Conversation; The Health Estates and Facilities Management Association 'HEFMA
15 Pulse' magazine);
- 16 • A half-day stakeholder symposium, the outputs of which will be made available online;
- 17 • A short video distilling the review findings via patient stories;
- 18 • Knowledge-To-Action Reports tailored to NHS Chief Executives, care home
19 managers, and estates/facilities managers, healthcare designers and builders.
20
21
22
23
24
25
26
27
28
29

30 REFERENCES

- 31 1. Dhargave P, Sendhilkumar R. Prevalence of Risk Factors For falls among Elderly People
32 Living in Long-Term Care Homes. *Journal of Clinical Gerontology and Geriatrics*.
33 2016;7(3):99-103.[doi:10.1016/j.jcgg.2016.03.004](https://doi.org/10.1016/j.jcgg.2016.03.004)
- 34 2. NHS Improvement. The Incidence and Costs of Inpatient Falls in Hospitals.2017. Available
35 from: https://improvement.nhs.uk/documents/1471/Falls_report_July2017.v2.pdf. (accessed
36 27/03/19)
- 37 3. World Health Organization. Who Global Report on Falls Prevention in Older Age.2008.
38 Available from: <http://www.who.int/iris/handle/10665/43811>. (accessed 14/03/19)
- 39 4. Rapp K, Becker C, Cameron ID, et al. Epidemiology of falls in residential aged care: analysis
40 of more than 70,000 falls from residents of Bavarian nursing homes. *J Am Med Dir Assoc*.
41 2012;13(2):187.e1-6.[doi: 10.1016/j.jamda.2011.06.011](https://doi.org/10.1016/j.jamda.2011.06.011)
- 42 5. Suzuki T, Sonoda S, Misawa K, et al. Incidence and Consequence of Falls in Inpatient
43 Rehabilitation of Stroke Patients. *Experimental Aging Research*. 2005;31(4):457-
44 69.[doi:10.1080/03610730500206881](https://doi.org/10.1080/03610730500206881)
- 45 6. Vergara I, Vrotsou K, Orive M, et al. Factors Related to Functional Prognosis in Elderly
46 Patients after Accidental Hip Fractures: A Prospective Cohort Study. *BMC Geriatr*.
47 2014;14:124.[doi:10.1186/1471-2318-14-124](https://doi.org/10.1186/1471-2318-14-124)
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 7. Santesso N, Carrasco-Labra A, Brignardello-Petersen R. Hip Protectors for Preventing Hip
4 Fractures in Older People. *Cochrane Database Syst Rev*.
5 2014(3).doi:10.1002/14651858.CD001255.pub5
6
- 7
8 8. Fischer I, Krauss M, Dunagan W, et al. Patterns and Predictors of Inpatient Falls and Fall-
9 Related Injuries in a Large Academic Hospital. *Infect Control Hosp*
10 *Epidemiol*, 2005;26(10):822-827.doi:10.1086/502500
- 11
12 9. National Institute for Health and Care Excellence. Falls in Older People: Assessing Risk
13 and Prevention. Clinical Guideline CG161.2013. Available from:
14 <https://www.nice.org.uk/guidance/cg161>. (accessed 14/03/19)
15
- 16
17 10. Royal College of Physicians. National Hip Fracture Database Annual Report 2017.2017.
18 Available from: <https://www.nhfd.co.uk/2017report>. (accessed 14/03/19)
- 19
20 11. Laing AC, Robinovitch SN. Low Stiffness Floors Can Attenuate Fall-Related Femoral
21 Impact Forces by up to 50% without Substantially Impairing Balance in Older Women. *Accid*
22 *Anal Prev*. 2009;41(3):642-50.doi:10.1016/j.aap.2009.03.001
23
- 24
25 12. Redfern MS, Moore PL, Yarsky CM. The Influence of Flooring on Standing Balance
26 among Older Persons. *Hum Factors*. 1997;39(3):445-55.doi:10.1518/001872097778827043
27
- 28
29 13. Glinka MN, Cheema KP, Robinovitch SN, et al. Quantification of the Trade-Off between
30 Force Attenuation and Balance Impairment in the Design of Compliant Safety Floors. *J Appl*
31 *Biomech*. 2013;29(5):563-72.doi:10.1123/jab.29.5.563
32
- 33
34 14. Beach R, Jackson K, Bigelow KE, editors. Effect of Compliant Flooring on Postural
35 Stability in an Older Adult Population. Proceedings of the 37th Annual Conference of the
36 American Society of Biomechanics; 2013; Omaha, Nebraska, USA.
- 37
38 15. Stephens JM, Goldie PA. Walking Speed on Parquetry and Carpet after Stroke: Effect
39 of Surface and Retest Reliability. *Clin Rehabil*. 1999;13(2):171-
40 81.doi:10.1191/026921599668553798
41
- 42
43 16. Drahota AK, Ward D, Udell JE, et al. Pilot Cluster Randomised Controlled Trial of
44 Flooring to Reduce Injuries from Falls in Wards for Older People. *Age Ageing*. 2013;42(5):633-
45 40.doi:10.1093/ageing/aft067
46
- 47
48 17. Lachance CC, Jurkowski MP, Dymarz AC, et al. Compliant Flooring to Prevent Fall-
49 Related Injuries in Older Adults: A Scoping Review of Biomechanical Efficacy, Clinical
50 Effectiveness, Cost-Effectiveness, and Workplace Safety. *Plos One*.
51 2017;12(2):23.doi:10.1371/journal.pone.0171652
52
- 53
54 18. Donald IP, Pitt K, Armstrong E, et al. Preventing Falls on an Elderly Care Rehabilitation
55 Ward. *Clin Rehabil*. 2000;14(2):178-85.doi:10.1191/026921500677888641
56
- 57
58 19. Gustavsson J, Bonander C, Andersson R, et al. Investigating the Fall-Injury Reducing
59 Effect of Impact Absorbing Flooring among Female Nursing Home Residents: Initial Results.
60 *Inj Prev*. 2015;21(5):320-4.doi:10.1136/injuryprev-2014-041468

20. Hanger HC, Hurley K, Hurring S, White A, editor Low Impact Flooring - Is It Practical in a Hospital? Proceedings of the 6th Biennial Australia and New Zealand Falls Prevention Conference; 2014; Sydney, Australia.
21. Healey F. Does Flooring Type Affect Risk of Injury in Older in-Patients? *Nurs Times*. 1994;90(27):40-1. <https://www.ncbi.nlm.nih.gov/pubmed/8047456>
22. Knoefel F, Patrick L, Taylor J, et al. Dual-Stiffness Flooring: Can It Reduce Fracture Rates Associated with Falls? *J Am Med Dir Assoc*. 2013;14(4):303-5. [doi:10.1016/j.jamda.2012.12.077](https://doi.org/10.1016/j.jamda.2012.12.077)
23. Simpson AH, Lamb S, Roberts PJ, et al. Does the Type of Flooring Affect the Risk of Hip Fracture? *Age Ageing*. 2004;33(3):242-6. [doi:10.1093/ageing/afh071](https://doi.org/10.1093/ageing/afh071)
24. Warren CJ, Hanger HC. Fall and Fracture Rates Following a Change from Carpet to Vinyl Floor Coverings in a Geriatric Rehabilitation Hospital. A Longitudinal, Observational Study. *Clin Rehabil*. 2013;27(3):258-63. [doi:10.1177/0269215512455530](https://doi.org/10.1177/0269215512455530)
25. Yarme J, Yarme H. Flooring and Safety. *Nursing Homes: Long Term Care Management*. 2001;50(10):82.
26. Lachance CC, Feldman F, Laing AC, et al. Study Protocol for the Flooring for Injury Prevention (Flip) Study: A Randomised Controlled Trial in Long-Term Care. *Inj. Prev*. 2016;22(6):453-60. [doi:10.1136/injuryprev-2016-042008](https://doi.org/10.1136/injuryprev-2016-042008)
27. Hanger HC. Low-Impact Flooring: Does It Reduce Fall-Related Injuries? *J Am Med Dir Assoc*. 2017;18(7):588-91. [doi:10.1016/j.jamda.2017.01.012](https://doi.org/10.1016/j.jamda.2017.01.012)
28. Gustavsson J, Bonander C, Nilson F. A Quasi-Experimental Evaluation of Compliant Flooring in a Residential Care Setting. *Plos One*. 2018;13(7). [doi:10.1371/journal.pone.0201290](https://doi.org/10.1371/journal.pone.0201290)
29. Gustavsson J, Rahm G, Jernbro C, et al. Effects of Impact-Absorbing Flooring in Residential Care from the Perspectives of Enrolled Nurses. *Journal of Housing for the Elderly*. 2017;31(4):367-81. [doi:10.1080/02763893.2017.1335670](https://doi.org/10.1080/02763893.2017.1335670)
30. Gustavsson J, Jernbro C, Nilson F. There Is More to Life Than Risk Avoidance - Elderly People's Experiences of Falls, Fall-Injuries and Compliant Flooring. *Int J Qual Stud Health Well-being*. 2018;13(1). [doi:10.1080/17482631.2018.1479586](https://doi.org/10.1080/17482631.2018.1479586)
31. Lachance CC, Zaborska VO, Leung PM, et al. Perceptions About Compliant Flooring from Senior Managers in Long-Term Care. *Journal of Housing for the Elderly*. 2018;32(2):194-210. [doi:10.1080/02763893.2018.1431584](https://doi.org/10.1080/02763893.2018.1431584)
32. Drahota A, Keenan B, Lachance C, et al. The SAFEST Review: The Shock-Absorbing Flooring Effectiveness Systematic Review including older adults and staff in care settings. 17/148 HTA Researcher-led Evidence Synthesis. HTA - 17/148/11.2019. Available from: <https://www.journalslibrary.nihr.ac.uk/programmes/hta/1714811/#/>. (accessed 14/03/19)

- 1
2
3 33. Drahota A, Bell M, Farrell-Savage K, et al. The SAFEST Review: The Shock-Absorbing
4 Flooring Effectiveness SysTematic Review including older adults and staff in care settings.
5 PROSPERO 2019. CRD42019118834. Available from:
6 http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42019118834.
7
8 (accessed 14/03/19)
9
10
11 34. Moher D, Shamseer L, Clarke M, et al . *Preferred reporting items for systematic review*
12 *and meta-analysis protocols (PRISMA-P) 2015 statement* . Syst
13 Rev 2015;4:1.doi:10.1186/2046-4053-4-1
14
15
16
17 35. Mitnitski A, Howlett SE, Rockwood K. Heterogeneity of Human Aging and Its
18 Assessment. *J Gerontol A Biol Sci Med Sci*. 2017;72(7):877-84.[doi:10.1093/gerona/glw089](https://doi.org/10.1093/gerona/glw089)
19
20 36. Ward D, Drahota A, Gal D, et al. Care Home Versus Hospital and Own Home
21 Environments for Rehabilitation of Older People. *Cochrane Database Syst Rev*.
22 2008(4):CD003164.[doi:10.1002/14651858.CD003164.pub2](https://doi.org/10.1002/14651858.CD003164.pub2)
23
24
25 37. Higgins JPT, Green S, editors. *Cochrane Handbook for Systematic Reviews of*
26 *Interventions* Version 5.1.0 [Updated March 2011].Available from
27 [Http://Handbook.Cochrane.Org](http://Handbook.Cochrane.Org): The Cochrane Collaboration; 2011.
28
29
30 38. Birge SJ. Osteoporosis and Hip Fracture. *Clin Geriatr Med*. 1993;9(1):69-86.
31 <https://www.ncbi.nlm.nih.gov/pubmed/8443741>
32
33 39. Brawley EC. Environment- a Silent Partner in Caregiving. In: Kaplan, M, Hoffman, SB,
34 editors. *Behaviors in Dementia: Best Practices for Successful Management*: Health
35 Professions Press; 1998. p. 107-24.
36
37 40. Canadian Agency for Drugs and Technologies in Health. Rubberized Flooring in Long
38 Term Care: Clinical Effectiveness and Cost-Effectiveness. Rapid Response Report: Summary
39 of Abstracts.2010. Available from:
40 https://cadth.ca/sites/default/files/pdf/K0269_Rubber_Flooring_in_LTC_final.pdf. (accessed
41 14/03/19)
42
43
44 41. Center for Healthcare Enviornmental Management. Proper Flooring: A Critical Measure
45 for Preventing Slips and Falls. *Healthc Hazard Manage Monit*. 2003;16(10):1-5,
46 <https://www.ncbi.nlm.nih.gov/pubmed/12817401>
47
48
49 42. Cummings SR, Melton LJ. Epidemiology and Outcomes of Osteoporotic Fractures.
50 *Lancet*. 2002;359(9319):1761-7.[doi:10.1016/S0140-6736\(02\)08657-9](https://doi.org/10.1016/S0140-6736(02)08657-9)
51
52
53 43. Hester AL. Preventing Injuries from Patient Falls. *American Nurse Today*. 2015;10(7):9-
54 12.
55
56 44. Tibbitts GM. Patients Who Fall: How to Predict and Prevent Injuries. *Geriatrics*.
57 1996;51(9):24-8, 31. <https://www.ncbi.nlm.nih.gov/pubmed/8814111>
58
59
60

- 1
2
3 45. Tideiksaar R. Mechanisms of Falls in Community Residing Older Persons. *Pride Institute*
4 *journal of long term home health care*. 1993.
- 5
6 46. Tideiksaar R, Fletcher B. Keeping Elderly on Their Feet. *Issues in Science and*
7 *Technology*. 1989;5(3):78-81.
- 8
9 47. Hales M, Johnson JD, Asbury G, et al. Influence of Floor Covering Composition on Force
10 Attenuation During Falls, Wheelchair Mobility, and Slip Resistance. *AATCC REV*. 2015;15:44–
11 53.[doi:10.14504/ar.15.6.4](https://doi.org/10.14504/ar.15.6.4)
- 12
13 48. Lange B. The Impact of Absorbent Floor in Reducing Hip Fractures: A Cost-Utility
14 Analysis among Institutionalized Elderly: Karlstad University; 2012.
- 15
16 49. Latimer N, Dixon S, Drahota AK, et al. Cost--Utility Analysis of a Shock-Absorbing Floor
17 Intervention to Prevent Injuries from Falls in Hospital Wards for Older People. *Age Ageing*.
18 2013;42(5):641-5.[doi:10.1093/ageing/aft076](https://doi.org/10.1093/ageing/aft076)
- 19
20 50. Njogu F, Brown P. Cost Effectiveness of Impact Absorbent Flooring in Reducing
21 Fractures among Institutionalized Elderly.2008. Available from:
22 [https://mafiadoc.com/queue/cost-effectiveness-of-impact-absorbent-flooring-in-](https://mafiadoc.com/queue/cost-effectiveness-of-impact-absorbent-flooring-in-5ba9567f097c47fb4e8b45e5.html)
23 [_5ba9567f097c47fb4e8b45e5.html](https://mafiadoc.com/queue/cost-effectiveness-of-impact-absorbent-flooring-in-5ba9567f097c47fb4e8b45e5.html).
- 24
25 51. Ryen L, Svensson M. Modelling the Cost-Effectiveness of Impact-Absorbing Flooring in
26 Swedish Residential Care Facilities. *Eur J Public Health*. 2016;26(3):407-
27 11.[doi:10.1093/eurpub/ckv197](https://doi.org/10.1093/eurpub/ckv197).
- 28
29 52. Soangra R, Jones B, Lockhart TE, editors. Effects of Anti-Fatigue Flooring on Gait
30 Parameters. Proceedings of the 54th Annual Meeting of the Human Factors and Ergonomics
31 Society; 2010; San Francisco, California, USA: SAGE Publications.
- 32
33 53. Zacker C, Shea D. An Economic Evaluation of Energy-Absorbing Flooring to Prevent
34 Hip Fractures. *Int J Technol Assess Health Care*. 1998;14(3):446-57,
35 <https://www.ncbi.nlm.nih.gov/pubmed/9780531>
- 36
37 54. Covidence systematic review software. Veritas Health Innovation. Melbourne,
38 Australia: Available at www.covidence.org.
- 39
40 55. Moher D, Liberati A, Tetzlaff J, et al. Preferred Reporting Items for Systematic Reviews
41 and Meta-Analyses: The Prisma Statement. *PLoS Med*.
42 2009;6(7):e1000097.[doi:10.1371/journal.pmed.1000097](https://doi.org/10.1371/journal.pmed.1000097)
- 43
44 56. Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic
45 Cochrane Centre, The *The Cochrane Collaboration*. 2014.
- 46
47 57. Schünemann H, Brożek J, Guyatt G, et al., editors. Grade Handbook for Grading Quality
48 of Evidence and Strength of Recommendations. Updated October 2013. The GRADE Working
49 Group, editor. Introduction to Grade Handbook. 2013.
- 50
51 58. GRADEpro GDT. Gradepro Guideline Development Tool [Software]. McMaster
52 University, 2015 (developed by Evidence Prime, Inc.). Available from grade.pro.org. 2015.
- 53
54
55
56
57
58
59
60

- 1
2
3 59. Lamb SE, Jørstad-Stein EC, Hauer K, et al. Development of a Common Outcome Data
4 Set for Fall Injury Prevention Trials: The Prevention of Falls Network Europe Consensus. *J*
5 *Am Geriatr Soc*. 2005;53(9):1618-22. doi:10.1111/j.1532-5415.2005.53455.x
6
7
8 60. Cameron ID, Robinovitch S, Birge S, et al. Hip Protectors: Recommendations for
9 Conducting Clinical Trials--an International Consensus Statement (Part Ii). *Osteoporos Int*.
10 2010;21(1):1-10. doi:10.1007/s00198-009-1055-2
11
12 61. Lachance CC, Mackey DC. Feasibility of Compliant Flooring in Long-Term Care: Results
13 from a Stakeholder Symposium. *Can J Aging*. 2018;37(1):84-
14 94. doi:10.1017/S0714980817000551
15
16 62. Higgins JPT, Sterne JAC, Savović J, et al. A Revised Tool for Assessing Risk of Bias in
17 Randomized Trials. In: Chandler J, McKenzie J, Boutron I, Welch V, editors. *Cochrane*
18 *Methods*. *Cochrane Database of Systematic Reviews*. 10 (Suppl 1)2016.
19
20 63. Sterne JA, Hernán MA, Reeves BC, et al. Robins-I: A Tool for Assessing Risk of Bias in
21 Non-Randomised Studies of Interventions. *BMJ*. 2016;355:i4919. doi:10.1136/bmj.i4919
22
23 64. Aromataris E, Munn Z, editors. Joanna Briggs Institute Reviewer's Manual.: The Joanna
24 Briggs Institute. Available from <https://reviewersmanual.joannabriggs.org/>; 2017.
25
26 65. Soilemezi D, Drahota A, Crossland J, et al. The Role of the Home Environment in
27 Dementia Care and Support: Systematic Review of Qualitative Research. *Dementia (London)*.
28 2017. doi:10.1177/1471301217692130
29
30 66. Garrison KR, Shemilt I, Donell S, et al. Bone Morphogenetic Protein (Bmp) for Fracture
31 Healing in Adults. *Cochrane Database Syst Rev*.
32 2010(6):CD006950. doi:10.1002/14651858.CD006950.pub2
33
34 67. Drummond MF, Jefferson TO. Guidelines for Authors and Peer Reviewers of Economic
35 Submissions to the BMJ. The Bmj Economic Evaluation Working Party. *BMJ*.
36 1996;313(7052):275-83,
37
38 68. Philips Z, Bojke L, Sculpher M, et al. Good Practice Guidelines for Decision-Analytic
39 Modelling in Health Technology Assessment: A Review and Consolidation of Quality
40 Assessment. *Pharmacoeconomics*. 2006;24(4):355-71. doi:10.2165/00019053-200624040-
41 00006
42
43 69. The GRADE-CERQual Project Group. How to Use and Interpret Findings from
44 Qualitative Evidence Syntheses Assessed Using the Cerqual Approach: A Practical Guide for
45 Decision Makers in Health and Social Care and Other Users.2018. Available from:
46 <https://www.cerqual.org/>. (accessed 13/03/19)
47
48 70. Lewin S, Booth A, Glenton C, et al. Applying Grade-Cerqual to Qualitative Evidence
49 Synthesis Findings: Introduction to the Series. *Implement Sci*. 2018;13(Suppl
50 1):2. doi:10.1186/s13012-017-0688-3
51
52
53
54
55
56
57
58
59
60

- 1
2
3 71. Wager E, Wiffen PJ. Ethical Issues in Preparing and Publishing Systematic Reviews. *J*
4 *Evid Based Med*. 2011;4(2):130-4. [doi:10.1111/j.1756-5391.2011.01122.x](https://doi.org/10.1111/j.1756-5391.2011.01122.x)
5
6 72. Graham ID, Logan J, Harrison MB, et al. Lost in Knowledge Translation: Time for a Map?
7 *J Contin Educ Health Prof*. 2006;26(1):13-24. [doi:10.1002/chp.47](https://doi.org/10.1002/chp.47)
8
9
10
11

12 **AUTHOR STATEMENT**

13
14 AD is Principal Investigator (guarantor) of the project, and was involved in the project
15 conception and design, and drafting of the protocol. BK, CL, AL, and DM were all involved in
16 the conception and design of the project, and revising the protocol content. JR contributed to
17 the design of the health economics component and revising the protocol. LF contributed to the
18 design of the Summary of Findings Tables component, and drafting of this manuscript. AD,
19 BK, CL, and JR were co-applicants on the original funding proposal to HTA. All authors are
20 also Advisory Board members and have read and approved the manuscript.
21
22
23
24
25
26
27

28 **ACKNOWLEDGEMENTS**

29
30 We would like to thank our public involvement members, Mrs Margaret Bell, Mrs Elizabeth
31 Burden, and Mrs Joleen Tobias, and further members of our Advisory Board: Nadra Ahmed
32 (National Care Association), Alison Cracknell (Leeds Teaching Hospitals NHS Trust), Kirsten
33 Farrell-Savage (University of Portsmouth), Olanrewaju Okunribido (Health & Safety
34 Executive), Jonathan Stewart (Health Estates and Facilities Management Association), Julie
35 Windsor (NHS Improvement), and Anna Winfield (Leeds Teaching Hospitals NHS Trust). Our
36 Advisory Board members have provided feedback and advice throughout the funding
37 application process and when designing the protocol, and have approved the protocol. OO
38 was also a co-applicant on the original funding proposal to HTA.
39
40
41
42
43
44
45

46 **FUNDING STATEMENT**

47
48 This report is independent research funded by the National Institute for Health Research
49 (NIHR Health Technology Assessment, 17/148/11 – The SAFEST Review: The Shock-
50 Absorbing Flooring Effectiveness SysTematic Review including older adults and staff in care
51 settings). The views expressed in this publication are those of the authors and not necessarily
52 those of the NHS, the National Institute for Health Research or the Department of Health and
53 Social Care. The Health & Safety Executive are supporting 10 days of Olanrewaju
54 Okunribido's time in kind on this project.
55
56
57
58
59
60

COMPETING INTERESTS STATEMENT

AD, CL, AL, and DM have undertaken studies that will be a part of this review.

AD and BK have been collaborating with members of the Health & Safety Laboratory (2018-present) on some unfunded academic research using a new testing procedure to assess the shock-absorbency of various floor coverings. Five flooring manufacturers delivered free samples to use in the project. AD and BK have no stake in any of these companies.

In 2015, AD was involved in a collaborative funding application with Polyflor for some SBRI Healthcare innovation funding. The application was short-listed but unsuccessful. AD has no stake in this company.

AL reports grants from SofSurfaces Inc, grants and personal fees from SorbaShock LLC, grants and personal fees from Viconic Sporting, outside the submitted work. AL is a member of an ASTM Work Group (WK38804) whose Technical Contact is the President of SATech. SATech has donated flooring materials to AL's laboratory that have formed the basis of several studies examining the biomechanical effectiveness of compliant flooring (i.e. safety flooring). He has never had (nor does he currently have) any financial links to the company.

CL is employed at the Canadian Agency for Drugs and Technologies in Health (CADTH).

JR is a member of the NIHR's HTA/EME editorial board (0.1 wte).


LF has nothing to disclose.

Additional Files

Supplementary file 1. PRISMA-P checklist.

Supplementary file 2. Medline search strategy

Figure 1. Theoretical framework of potential effect modifiers.



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

PRISMA- P 2015 Checklist

This checklist has been adapted from the operationalized checklist available from: <http://www.prisma-statement.org/Extensions/Protocols.aspx> which is based on Table 3 in Moher et al. Syst Rev. 2015;4(1):1. doi: 10.1186/2046-4053-4-1

Section/topic	#	Checklist item	Information reported		Page number(s)
			Yes	No	
ADMINISTRATIVE INFORMATION					
Title					
Identification	1a	Identify the report as a protocol of a systematic review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	<input type="checkbox"/>	<input checked="" type="checkbox"/>	n/a
Registration	2	If registered, provide the name of the registry (e.g., PROSPERO) and registration number in the Abstract	<input checked="" type="checkbox"/>	<input type="checkbox"/>	2
Authors					
Contact	3a	Provide name, institutional affiliation, and e-mail address of all protocol authors; provide physical mailing address of corresponding author	<input checked="" type="checkbox"/>	<input type="checkbox"/>	1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	22
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	<input checked="" type="checkbox"/>	<input type="checkbox"/>	5
Support					
Sources	5a	Indicate sources of financial or other support for the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	22
Sponsor	5b	Provide name for the review funder and/or sponsor	<input checked="" type="checkbox"/>	<input type="checkbox"/>	22
Role of sponsor/funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	<input checked="" type="checkbox"/>	<input type="checkbox"/>	22
INTRODUCTION					
Rationale	6	Describe the rationale for the review in the context of what is already known	<input checked="" type="checkbox"/>	<input type="checkbox"/>	4
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	5
METHODS					

Section/topic	#	Checklist item	Information reported		Page number(s)
			Yes	No	
Eligibility criteria	8	Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	5-7
Information sources	9	Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage	<input checked="" type="checkbox"/>	<input type="checkbox"/>	7-8
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Supplementary file 2
STUDY RECORDS					
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	8
Selection process	11b	State the process that will be used for selecting studies (e.g., two independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	9
Data collection process	11c	Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	<input checked="" type="checkbox"/>	<input type="checkbox"/>	9,11
Data items	12	List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications	<input checked="" type="checkbox"/>	<input type="checkbox"/>	9
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	<input checked="" type="checkbox"/>	<input type="checkbox"/>	9,10
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	<input checked="" type="checkbox"/>	<input type="checkbox"/>	10 (quantitative), 12 (qualitative)
DATA					
Synthesis	15a	Describe criteria under which study data will be quantitatively synthesized	<input checked="" type="checkbox"/>	<input type="checkbox"/>	11-12
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data, and methods of combining data from studies, including any planned exploration of consistency (e.g., I^2 , Kendall's tau)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	11-12
	15c	Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, meta-regression)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	12
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	<input checked="" type="checkbox"/>	<input type="checkbox"/>	12, 13
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective reporting within studies)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	10, 11

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Section/topic	#	Checklist item	Information reported		Page number(s)
			Yes	No	
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (e.g., GRADE)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	13,14

For peer review only

Medline search strategy

Search line	Terms
1	MH "Wounds and Injuries+
2	MH "Accidental Falls/PC"
3	MH "Hip Fractures+/PC"
4	falls
5	faller\$
6	S1 OR S2 OR S3 OR S4 OR S5
7	MH "Aged+"
8	MH "Middle Aged"
9	Older
10	Senior\$
11	elderly
12	S7 OR S8 OR S9 OR S10 OR S11
13	S6 AND S12
14	MH "Residential Facilities+"
15	MH "Long-Term Care"
16	MH "Institutionalization"
17	MH "Hospitalization"
18	MH "Subacute Care"
19	MH "Hospitals+"
20	MH "Hospital Units"
21	MH "Rehabilitation Centers"
22	MH "Inpatients"
23	MH "Geriatric Assessment"
24	("long stay" or "long term" or "acute" or "sub-acute" or "subacute" or "residential" or "hospital") N3 (care or ward# or hospital)
25	(rehabilitation or geriatric) N1 (ward# or hospital# or unit# or department#)
26	hostel\$ or nursing home\$
27	inpatient
28	resident\$
29	institution\$
30	S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29
31	S13 and S30
32	floor* NOT (pelvic floor OR sinus OR mouth)
33	carpet*
34	ground surface\$
35	smartcell*
36	tarkett
37	softile
38	sorbashock
39	forbo
40	kradal
41	noraplan
42	MH "Floors and Floorcoverings"
43	S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42
44	S31 AND S43
45	MH "Animals+"
46	MH "Humans"
47	S45 NOT S46
48	S44 NOT S47
49	S44 NOT S47 Limiters - Date of Publication: 20160501-

BMJ Open

Protocol for The SAFEST Review: The Shock-Absorbing Flooring Effectiveness Systematic Review including older adults and staff in hospitals and care homes

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-032315.R1
Article Type:	Protocol
Date Submitted by the Author:	07-Nov-2019
Complete List of Authors:	Drahota, Amy; University of Portsmouth, School of Health & Care Professions Felix, Lambert; University of Portsmouth, School of Health & Care Professions Keenan, Bethany; Cardiff University, School of Engineering Lachance, Chantelle; University of Portsmouth, School of Health & Care Professions Laing , Andrew Laing ; University of Waterloo, Department of Kinesiology Mackey, Dawn ; Simon Fraser University, Department of Biomedical Physiology and Kinesiology Raftery, James; University of Southampton, Wessex Institute
Primary Subject Heading:	Evidence based practice
Secondary Subject Heading:	Geriatric medicine, Nursing, Health economics, Health services research
Keywords:	Floors and Floorcoverings, Accidental Falls, Wounds and Injuries, Hospitals, Residential Facilities

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 **Protocol for The SAFEST Review: The Shock-Absorbing Flooring**
5 **Effectiveness SysTematic Review including older adults and staff in hospitals**
6 **and care homes**
7

8 PROSPERO registration number: CRD42019118834
9

10 **Corresponding Author**
11

12
13 Amy Drahota, <http://orcid.org/0000-0001-9772-0220>
14 Reader in Health & Social Care Evidence & Evaluation,
15 School of Health & Care Professions,
16 University of Portsmouth,
17 St Andrews Court,
18 St Michael's Road, Portsmouth, Hampshire,
19 PO1 2PR, UK
20 Telephone: +44 (0)23 92 84 4432
21 Email: amy.drahota@port.ac.uk
22
23
24
25

26 **Co-authors**

- 27 1. Lambert M Felix, <http://orcid.org/0000-0001-6517-9089>
28 Email: lambert.felix@port.ac.uk
29 School of Health & Care Professions, University of Portsmouth, Portsmouth, UK
30
31
32 2. Bethany Keenan, <https://orcid.org/0000-0001-7787-2892>
33 Email: KeenanB@cardiff.ac.uk
34 School of Engineering, University of Cardiff, Cardiff, UK
35
36
37 3. Chantelle C Lachance, <http://orcid.org/0000-0001-5755-5160>
38 Email: chantelle.lachance@port.ac.uk
39 School of Health & Care Professions, University of Portsmouth, Portsmouth, UK
40
41
42 4. Andrew C Laing, <https://orcid.org/0000-0001-8128-011X>
43 Email: actlaing@uwaterloo.ca
44 Department of Kinesiology, University of Waterloo, Waterloo, Canada
45
46
47 5. Dawn C Mackey, <http://orcid.org/0000-0001-9854-1486>
48 Email: dmackey@sfu.ca
49 Department of Biomedical Physiology and Kinesiology, Simon Fraser University,
50 Burnaby, Canada
51
52
53 6. James Raftery,
54 Email: J.P.Raftery@soton.ac.uk
55 Wessex Institute, University of Southampton, Southampton, UK
56

57 Word count: 4026

58 Key words: Floors and Floorcoverings; Accidental Falls; Wounds and Injuries; Hospitals;
59 Residential Facilities.
60

ABSTRACT

Introduction: Falls in hospitals and care homes are a major issue of international concern. Inpatient falls are the most commonly reported safety incident in the United Kingdom's National Health Service (NHS), costing the NHS £630 million a year. Injurious falls are particularly life-limiting and costly. There is a growing body of evidence on shock-absorbing flooring for fall-related injury prevention; however, no systematic review exists to inform practice.

Methods and analysis: We will systematically identify, appraise, and summarise studies investigating the clinical and cost-effectiveness, and experiences of shock-absorbing flooring in hospitals and care homes. Our search will build on an extensive search conducted by a scoping review (inception to May 2016). We will search electronic databases (AgeLine, CINAHL, MEDLINE, NHS Economic Evaluation Database, Scopus, and Web of Science; May 2016 – present), trial registries, and grey literature. We will conduct backward and forward citation searches of included studies, and liaise with study researchers. We will evaluate the influence of floors on fall-related injuries, falls, and staff work-related injuries through randomised and non-randomised studies, consider economic and qualitative evidence, and implementation factors. We will consider risk of bias, assess heterogeneity, and explore potential effect modifiers via subgroup analyses and sensitivity analyses. Where appropriate we will combine studies through meta-analysis. We will use the GRADE approach to evaluate the quality of evidence and present the results using summary of findings tables, and adhere to the PRISMA reporting guidelines.

Ethics and dissemination: We will follow the ethical principles of systematic review conduct, by attending to publication ethics, transparency, and rigour. Our dissemination plan includes peer-reviewed publication, presentations, press release, stakeholder symposium, patient video, and targeted knowledge-to-action reports. This review will inform decision-making around falls management in care settings and identify important directions for future research.

Funding and registration: The systematic review is funded by the NIHR HTA Programme (Project ref 17/148/11), and registered in PROSPERO ([CRD42019118834](https://doi.org/10.1111/CRD4.2019118834)).

ARTICLE SUMMARY

Strengths and limitations of this study

- This will be a mixed methods systematic review including randomised and non-randomised clinical studies, economic and qualitative evidence;

- Studies will be assessed using the updated Cochrane risk of bias tools for quantitative evidence, and Joanna Briggs Institute method for qualitative studies;
- Analyses will be at the study level, which limits the scope for exploring moderating factors related to patient-level characteristics on the effectiveness of flooring interventions;
- The quality of the evidence will be summarised using the GRADE approach, with the strength of the review's findings limited to the quantity and internal validity of the included studies;
- We will be guided by the Knowledge-to-Action Framework to facilitate the translation of the findings into practice.

INTRODUCTION

Falls in health and social care settings are a major concern for older adults globally, causing morbidity, mortality and economic burden (1-3). Falls have been climbing the league tables of the leading causes of global disability-adjusted life years (4), with falls and injury rates in residential care settings substantially higher than that of older people living in the community (1). In the United Kingdom (UK), inpatient falls are the most commonly reported safety incident with over 250,000 reported per year in the National Health Service (NHS) in England alone (5). Falls have a complex aetiology of intrinsic (e.g. co-morbidities, cognitive function, mobility) and extrinsic (e.g. environmental design, staffing, footwear, medication) risk factors (3, 6-8) and no single solution effectively prevents them. A systematic review of falls prevention interventions in institutional settings (9), found low quality evidence, with uncertain conclusions for a range of interventions including: exercise, physiotherapy, sensor alarms, and multifactorial interventions. This review excluded studies targeting fall-related injury prevention, yet the prevention of severe falls is considered a priority (5). One of the most severe consequences of falls are hip fractures, but wearable hip protectors have poor compliance, which is a barrier to their use (10). Unlike hip protectors, manipulating the physical environment is a promising intervention for reducing injurious falls as it requires no compliance from patients or staff, and can accommodate other injury types.

Shock-absorbing flooring can reduce the impact forces of falls by decreasing the stiffness of the ground surface (11). However, softer floors could negatively impact on gait, potentially leading to increased falls risk (11-15). The potential benefits and risks of shock-absorbing floors may vary depending on the type of patient utilising them. Furthermore, adverse effects of shock-absorbing floors may present in staff if greater effort is required to manoeuvre rolling equipment, potentially increasing injury risk (16).

There has been no comprehensive systematic review focussing on flooring interventions in healthcare settings for fall-related injury prevention. A recent scoping review of flooring interventions involved a thorough search of the literature, however, it did not involve a critical appraisal or systematic synthesis (17). A systematic review of studies identified in the scoping review (16,18-25) as well as more recent studies (26-31), will provide a more reliable basis for decision-making and identify the next steps for research.

This publication is an abridged version of the full protocol (32), and is registered on PROSPERO ([CRD42019118834](https://doi.org/10.1111/CRD4.2019118834)) (33). Any important protocol amendments will be published on these platforms (32-33). We have conformed to the Preferred Reporting Items for

1
2
3 Systematic Review and Meta-Analysis Protocols (PRISMA-P) (34) in the writing of this
4 protocol (supplementary file 1).
5
6

7 **Aims and Objectives**

8
9 We aim to systematically review the evidence on shock-absorbing flooring use in care settings
10 (hospitals and care homes) for fall-related injury prevention in older adults. Specifically, we
11 will:
12

- 13 1. Assess the potential benefits (fall-related injury prevention) and risks (falls; staff injuries)
14 of different flooring systems in care settings.
- 15 2. Assess the extent to which these potential benefits and risks may be modified by different
16 study/setting, intervention, and participant characteristics.
- 17 3. Critically appraise and summarise current evidence on the resource use, costs and cost-
18 effectiveness of shock-absorbing flooring in care settings for older adults, compared with
19 standard flooring.
- 20 4. Summarise findings on the implementation of flooring interventions in the included studies.
- 21 5. Summarise the views and experiences of shock-absorbing flooring use from staff,
22 patients'/residents', and visitors' perspectives.
- 23 6. Identify gaps in existing evidence.
24
25
26
27
28
29
30
31
32
33
34

35 **METHODS**

36 **Eligibility criteria**

37 **Population**

38 The target population for the intervention to potentially benefit is older adults in care settings.
39 We have no set cut-off criteria for age, as chronological age may not be a good indicator of
40 frailty (35). Studies must focus on adult populations to be included; studies focussing solely
41 on children will be excluded. We are also interested in staff outcomes.
42
43

44 **Setting**

45 Studies must have been conducted in a care setting (defined below) including hospitals (acute,
46 sub-acute), intermediate and long-term care settings (nursing and care homes). Studies
47 conducted in people's own homes, or other settings (e.g. playgrounds, sporting venues) will
48 be excluded.
49
50
51
52
53
54
55
56
57
58
59
60

Care settings will be broadly defined as (36):

- Care home environments (a facility that provides: communal living facilities for long-term care; overnight accommodation; nursing or personal care; for people with illness, disability or dependence).
- Hospital environments (a facility that provides: communal care where there is an expectation that this care is time limited; overnight accommodation; nursing and personal care for people with illness and disability).

Interventions

Interventions may include flooring systems which have been purposely designed to prevent fall-related injuries (e.g. SmartCells, Sorbashock, Kradal), thick vinyl (>5mm thick; e.g. sports floors, such as Tarkett Omnisports Excel), carpet with or without underlay, and other combination flooring systems (e.g. vinyl overlays with padded underlays, such as foam or rubber, or wooden subfloors). Alternative terminology for the intervention may include variations on the terms: compliant flooring, safety flooring, soft flooring, impact absorbing flooring, energy absorbing flooring, low-impact flooring, dual stiffness flooring, low stiffness flooring, absorptive surfaces, cushioned flooring, rubber flooring, acoustic flooring, and carpet.

We will exclude studies reporting exclusively on mats as they are not permanently affixed to the floor and do not provide universal coverage or protection; mats have different implications for installation and practice and are not the focus of this review. Studies in which flooring is one component of a package of interventions and the effects of the floor cannot be distinguished from concurrent interventions will be excluded.

Comparator

Our main control group is standard or rigid flooring (e.g. concrete subfloor, ≤2mm vinyl/resilient flooring). We will include head-to-head comparisons of different types of shock-absorbing flooring systems where possible. Studies may compare any combination of flooring systems (subfloors and overlays).

Outcomes

The reporting of specific outcomes does not form part of our eligibility criteria for studies to be included in this review.

Study Design

We will include randomised, non-randomised, observational, economic, and qualitative studies. Whilst randomised trials of flooring are feasible, the nature and logistics of the

intervention make observational and opportunistic quasi-experimental designs more practical. Studies will be classified according to their component design features using the study design features presented in the Cochrane Handbook (37). The following study designs will be eligible:

- Individually or cluster randomised controlled trials;
- Quasi experimental studies where allocation is non-random;
- Interrupted times series;
- Controlled before and after studies;
- Cohort studies;
- Case-control studies;
- Partial and full economic evaluations, based on a single study or model;
- Qualitative studies to explore experiences, attitudes, and perceptions towards flooring interventions.

We will exclude simple before and after studies measuring quantitative outcomes, with no evaluation of time trends or concurrent control.

Information sources and search strategy

To avoid duplication of effort, we will build on the search already conducted in a scoping review (17), which completed its search in May 2016. The clinical (12, 16, 18-26, 38-46) and cost-effectiveness (11, 21, 26, 40-41, 47-63) records identified in the scoping review will be assessed for inclusion in the current review. We will continue the search from May 2016 to present, and will not apply any language restrictions. A comprehensive search, as listed in Table 1, will be undertaken, to include electronic databases, grey literature, hand searches, citation screening, and expert consultation.

SEARCH TYPE	INFORMATION SOURCES
Electronic Databases	AgeLine (EBSCO) CINAHL Complete (EBSCO) MEDLINE (EBSCO) NHS Economic Evaluation Database (Centre for Reviews and Dissemination) Scopus Web of Science (Thomson Reuters)
Grey literature search	Clinical trial registries WHO International Clinical Trials Registry Platform (ICTRP) Theses/dissertations ProQuest Theses and Dissertations Abstracts/conference proceedings Biennial Conference of the Australian and New Zealand Falls Prevention Society

Canadian Association on Gerontology Annual Scientific and Educational Meeting
 Gerontological Society of America's Annual Scientific Meeting
 International Society for Posture and Gait Research World Congress
 World Conference of Gerontechnology
 World Congress of the International Association of Gerontology and Geriatrics
Websites
 Agency for Healthcare Research and Quality (AHRQ)
 Canadian Agency for Drugs and Technologies in Health (CADTH)
 NHS Improvement
 NICE Guidelines
 Open Grey (opengrey.eu)
 Parachute Canada
 The National Institute for Occupational Safety and Health (NIOSH)
 The International Network of Agencies for Health Technology Assessment
 UK Health Technology Assessment
 US Center for Health Design
 WHO Health Evidence Database (HEN)

Hand searching and citation screening

Reference lists

References of included studies
 Forward citation searching of included studies in Web of Science

Journal

Age and Ageing

Table 1: List of information sources

We have adapted the broader search strategy of the scoping review (17) to make it more specific to the current study (The SAFEST Review). The strategy for MEDLINE (supplementary file 2) is based on our eligibility criteria and uses a combination of keyword synonyms and controlled vocabulary terms (e.g., MeSH). We will adapt the MEDLINE search for other information sources.

Study Records

Data management

We will import the search records into EndNote™ online and use Covidence (54) to support duplicate record identification, screening, data collection, and risk of bias assessment processes, identification and resolution of discrepancies, and producing a PRISMA flow diagram (55). Data analyses will be undertaken in RevMan (56), and Summary of Findings Tables and Evidence Profiles will be created using GRADE Pro (57-58).

Selection process

We will screen titles, abstracts, and full reports independently in duplicate using an eligibility checklist. All records included in the clinical and cost-effectiveness sections of the scoping review will be assessed at the full report stage. From the results of the updated search, we will begin by screening titles, and those that look potentially relevant will be reviewed in abstract form. We will then screen the full texts of records that appear definitely or possibly relevant. Discrepancies will be resolved through a third independent arbitrator.

Data collection process

Our theoretical framework of potential effect modifiers (Figure 1) will underpin the data collection process. We will develop and pilot the data collection form with a data collection manual. Two reviewers will independently undertake data collection and assessment of risk of bias.

Data collection will include the following key components of information:

- Study identification
- Time/duration and geographical place of conduct
- Participant characteristics
- Intervention(s)
- Control(s)
- Outcome data acquisition: Method of falls reporting; Classification system of injuries; Identification of fractures (confirmation of diagnosis/type of fractures included); Identification of adverse effects.
- Setting
- Study design
- Risk of bias
- Outcomes data
- Patient and public involvement in the research
- Follow-up questions for study authors.

Outcomes and prioritization

There is no core outcome set specifically for flooring interventions; however we have considered the common outcome data set for fall injury prevention trials in community-dwelling populations (59) and the international consensus statement for trials on hip protectors (60). Recognising the unique features of our review and through stakeholder engagement (61) and

1
2
3 discussion with our public involvement group, we have prioritised the following outcome
4 measures:
5

- 6
- 7
- 8 • Primary outcomes: Injurious falls rate per 1000 patient-bed days;
- 9 • Falls rate per 1000 patient-bed days;
- 10

11 These measures assess the potential benefits and harms of flooring interventions for
12 patients/residents, accounting for occupancy levels and follow-up time; injurious falls rate
13 additionally accounts for variations to the underlying falls rate, as a pragmatic measure of
14 effectiveness.
15
16

17
18
19 Secondary outcomes:

- 20
- 21 • Number of falls with injuries (e.g. none, minor, moderate, severe, death)
- 22 • Number of fractures
- 23 • Number of hip fractures
- 24 • Number of fallers (risk of falling ≥ 1 times)
- 25 • Number of adverse events (e.g. staff injuries as defined by study authors)
- 26 • Number of head injuries
- 27 • Fractures per 1000 patient-bed days;
- 28 • Hip fractures per 1000 patient-bed days
- 29 • Qualitative outcomes (e.g. staff, patients/residents, visitors attitudes, views, and
30 experiences)
- 31 • Economic outcomes (to include assessments of quality-adjusted life years)
- 32 • Process outcomes (e.g. ease of, or problems with, flooring installation)
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42

43 **Risk of bias in individual studies**

44
45 Risk of bias assessment will be undertaken using the updated Cochrane risk of bias tool (ROB
46 2.0) for randomised trials (62) and the ROBINS-I (Risk Of Bias In Non-randomised Studies of
47 Interventions) tool (63) for other quantitative designs. We will assess the risk of bias at the
48 level of study results. Review authors will not be blinded during risk of bias assessments;
49 however, where they have been involved in co-authoring an included study, assessments will
50 be undertaken by at least two other independent reviewers. Supporting information and
51 justification for judgements (high; low; some concerns) will be recorded for each bias domain.
52 We will follow the guidance to derive summary judgements for each outcome, which will be
53 used to inform our sensitivity analyses and GRADE assessments (57).
54
55
56
57
58
59
60

Data analysis (quantitative studies)

Dealing with missing data

We will seek further information from study authors where required. If missing data are from participant/cluster dropouts, analyses will be based on the available data and an assessment of the problem will be included as part of our risk of bias judgements.

Measures of treatment effect

We will report rates of injurious falls, falls, and fractures using incidence rate ratios and 95% confidence intervals (CI). We will use risk ratios (95% CI) to describe number of fallers, number of falls with fall-related injuries, and number of participants with fall-related fractures or head injuries. Where available we will also report hazard ratios for falls including all falls from recurrent fallers. For non-randomised studies, we will record the unadjusted and adjusted estimates and note the factors adjusted for. Where multiple adjusted estimates are presented, we will extract the estimate highlighted as the primary model by the authors, or where this is unclear, take the model which has adjusted for the most covariates. Where rate ratios or risk ratios are not reported, we will calculate them where feasible (37).

Where studies present a break-down of the severity of injuries (as ordinal outcome data, e.g. none, mild, moderate, severe, death), we will present these descriptively, and if studies have used similar categorisation systems, using figures where feasible. We will report adverse events to staff as a risk or rate ratio (per 100 working staff-days) where possible, or as the number of events observed during the follow-up period, if no clear denominator is known.

Unit of analysis issues

To avoid the issue of double counting, we will link multiple associated publications together. When primary studies include multiple study arms, we will either combine the groups (if logical) or include only one pair-wise comparison (intervention versus control) in any one analysis. In the case of cluster randomised trials we will take clustering into account, and plan to adjust the estimates using an intra-cluster correlation coefficient (ICC) borrowed from another similar study if required (37).

Assessment of reporting bias

Where possible, we will produce funnel plots with different plotting symbols to identify subgroups. Funnel plot asymmetry will be tested if there are sufficient data (at least 10 studies to be combined), and visual inspection of the plots will be used to interpret the findings.

Data synthesis

Should meta-analysis be viable, studies will be combined using a random-effects model, assuming that intervention effects are likely to vary across studies (Figure 1). We will use the generic inverse variance data type to produce forest plots in RevMan (56); this method requires entering the natural logarithm of the rate ratio or risk ratio and its standard error for each study. We will use 95% CIs throughout. Where evidence exists from randomised and non-randomised studies, we will report the data separately, giving more emphasis to the findings from randomised trials. We will organise non-randomised studies according to whether data collection was prospective or retrospective, and if controls were concurrent or historical. If appropriate, we will combine the data from randomised and non-randomised studies to provide an overall summary effect estimate.

Assessment of heterogeneity

Heterogeneity will be explored irrespective of whether we decide to pool studies in a meta-analysis. Heterogeneity will be assessed through a combination of visual inspection of the forest plots, along with consideration of tests for homogeneity (Chi^2 with statistical significance set at $P < 0.10$), and measures for inconsistency (I^2) and heterogeneity (tau^2).

Where feasible, we plan to undertake subgroup analysis based on:

- Study design (randomised, non-randomised);
- Study setting (hospital, care home);
- Acuity of care (acute, sub-acute, intermediate, long-term care); and
- Flooring type (novel shock-absorbing flooring, thick vinyl/vinyl & underlay, carpet, wooden subfloor)

Sensitivity analyses

Sensitivity analyses will be undertaken based on:

- Risk of bias (e.g. removing studies at high risk of bias on the ROB2.0 tool, or critical/serious risk of bias on the ROBINS-I tool);
- Choice of effect estimates (e.g. where multiple adjusted estimates are reported, the analysis will be run on the most optimistic and pessimistic scenarios); and
- Adjustment for clustering where an ICC has been borrowed from another study (e.g. we will assess the impact of opting for more or less conservative adjustments).

Synthesis of Qualitative Studies

A meta-aggregative approach will be used to synthesise data from qualitative studies (64). We will derive generalizable statements, in the form of recommendations that can be used to guide end-users of the review (e.g. NHS Chief Executives, care home managers, estates/facilities managers, healthcare designers and builders, health and social care professionals, patients, residents, and carers). Studies will be critically assessed using the Joanna Briggs Institute's critical appraisal tool (64). We will follow the data collection process as above, and use QSR NVivo software for data analysis (65).

Synthesis of economic evidence

We will align our approach for the incorporation of costs data to an exemplar systematic review by Garrison and colleagues (66). One reviewer (LF) will extract all data from included economic evaluations, which will be checked by an expert reviewer (JR). Our data extraction form will be based on the format and guidelines used to produce structured abstracts of full economic evaluations for inclusion in the NHS Economic Evaluation Database. The methodological quality of included economic evaluations will be assessed through the use of recognised checklists based on guidelines for economic submissions to the British Medical Journal (for economic evaluations based on a single study) (67), and for quality assessment in economic decision-analytic models (for model-based economic evaluations) (68). Data extraction will include study characteristics such as country, settings, aims, and methodological aspects related to economic evaluation, individual items within the respective checklists (67-68), and the economic variables. We will collect the following economic variables, if reported: costs of flooring (purchasing, installation, maintenance); costs of falls based on injury, such as hospital resources (e.g. increased length of stay, additional surgery needs), and post-discharge healthcare cost (e.g. hospital readmission, outpatient visits); utility measures such as quality of life, life years and quality adjusted life years; and summary measures such as incremental cost-effectiveness ratio (ICERs), net monetary benefits, and value of information (Vol).

We will classify economic evaluations by type (*Partial evaluations*: 'outcome description', 'cost description', 'cost-outcome description', 'efficacy or effectiveness evaluation', or 'cost-analysis'; *Full economic evaluations*: 'cost-effectiveness analysis', 'cost-utility analysis', or 'cost-benefit analysis') and as either an economic evaluation based on a single study or a model-based economic evaluation. Where necessary, additional information from study authors will be sought.

1
2
3
4
5 Results will be tabulated and summarised narratively in the text. We will adjust all costs to
6 2019 Pound Sterling values using Gross Domestic Product deflators, and use relevant
7 exchange rates for international comparisons.
8
9

10 **Confidence in Cumulative Evidence**

11 Quantitative Evidence

12
13 The quality of evidence will be assessed across the included studies at outcome level for each
14 comparison using GRADE (57), and incorporated into Summary of Findings (SoF) Tables
15 using the GRADEpro software (58). Our main comparison will be 'shock-absorbing flooring
16 versus standard flooring', and we will include separate SoF tables for hospitals and care
17 homes. Supplementary SoF tables will be developed for different types of shock-absorbing
18 floors versus standard flooring, and for head-to-head comparisons of different shock-
19 absorbing flooring interventions.
20
21

22
23 The following outcomes will be included: 1) injurious falls rate per 1000 patient-bed days; 2)
24 falls rate per 1000 patient-bed days; 3) number of falls with injuries (e.g. none, minor,
25 moderate, severe); 4) number of fractures; 5) number of hip fractures; 6) number of fallers;
26 and 7) number of adverse events related to staff injuries. We will create supporting 'Evidence
27 profile' tables (57). The GRADE system provides a grade of the overall quality of the evidence
28 for each outcome on one of four levels: high, moderate, low, very low.
29
30
31
32
33
34
35

36 Qualitative Evidence

37
38 The CERQual group's recommendations will be followed to assess the quality of qualitative
39 evidence included in the review (69). Each review finding will be assessed based on
40 methodological limitations, coherence, adequacy of data, and relevance (70). We will make
41 an overall assessment of confidence for each review finding on one of the four levels: high,
42 moderate, low, very low. Assessments will be presented in 'CERQual Evidence profile', and
43 'Summary of Qualitative Findings (SoQF)' tables.
44
45
46
47
48
49

50 **ENGAGEMENT WITH STAKEHOLDERS**

51
52 We will consult with key stakeholders and a range of potential knowledge users during our
53 review. Our Advisory Board includes the following knowledge users: Falls in older people NICE
54 Guideline Developer; Safety and Improvement Clinical Lead (Leeds Teaching Hospitals NHS
55 Trust); director/chairman of the Health Estates and Facilities Management Association;
56 chairman of the National Care Association; public members; and shock-absorbing flooring
57
58
59
60

1
2
3 researchers from health sciences and engineering disciplines in the UK and Canada.
4 Collectively, members of the board possess the relevant expertise and decision-making
5 authority to critically evaluate and implement shock-absorbing flooring systems in high-risk
6 environments such as hospitals and long-term care in the UK, and utilise systematic review
7 evidence to inform future research.
8
9
10

11
12 An interactive process of communication between researchers and the Advisory Board will be
13 used throughout the review process. We will involve the Board in a number of important ways:
14 (1) in providing input on the design and implementation of the review; (2) as members of the
15 project team who attend project meetings and inform us of emerging primary research
16 evidence; (3) in the interpretation of findings and identification of research gaps; and (4) in the
17 packaging and dissemination of the review's findings in a form that is relevant, practical and
18 easily interpreted by other decision-makers and knowledge users.
19
20
21
22
23

24 25 **PATIENT AND PUBLIC INVOLVEMENT (PPI)**

26
27
28 Three public members engaged actively in the preparation of our funding proposal. They
29 informed our decisions relating to methodology, particularly prioritising outcomes, confirming
30 settings, and development of the theoretical framework.
31
32

33
34 The public members will participate in five specific PPI meetings over the course of the project.
35 Each meeting will include a brief training session to explain the stage of the review the project
36 is at, and the processes and tasks involved. They will contribute to the conduct of the
37 systematic review in the following ways: (1) Commenting on the clarity and
38 comprehensiveness of the protocol; Providing an independent judgement as to the fairness,
39 transparency, and consistency of (2) the risk of bias, and (3) GRADE judgements made by
40 the project team; (4) Providing feedback on the clarity of information presented in the
41 Summary of Findings Tables, as well as the order and presentation of comparisons and
42 subgroups; and (5) Providing feedback on the clarity, comprehensiveness, and presentation
43 of the project outputs (including the Plain English Summary).
44
45
46
47
48
49
50

51 52 **ETHICS AND DISSEMINATION**

53 We do not need to obtain ethical review, as this is an evidence synthesis. Nonetheless, our
54 ethical considerations (71) will relate to: 1) appropriateness of authorship on the final works;
55 2) avoidance of duplication in the publication of the findings; 3) avoiding plagiarism by ensuring
56 that all reported findings are sufficiently cited and attributable to the source material; 4)
57 transparency, in the form of acknowledging all contributions and competing interests ; 5)
58
59
60

1
2
3 having due rigour in the data collection and reporting phases of the review to ensure the
4 accuracy of the findings; and 6) flagging suspected fraudulent or plagiarised research to the
5 publishing journals.
6
7

8
9 Our research approach is underpinned by the Knowledge to Action Framework (72), and will
10 ensure involvement of knowledge users with researchers throughout the process.
11

12 We will disseminate our research outputs using the following media:
13

- 14 • Open access peer-reviewed journal publication;
- 15 • Presentations at national and international conferences, and a webinar;
- 16 • Press release/social media with an item in relevant media outlets (e.g. The
17 Conversation; The Health Estates and Facilities Management Association 'HEFMA
18 Pulse' magazine);
- 19 • A half-day stakeholder symposium, the outputs of which will be made available online;
- 20 • A short video distilling the review findings via patient stories;
- 21 • Knowledge-To-Action Reports tailored to NHS Chief Executives, care home
22 managers, and estates/facilities managers, healthcare designers and builders.
23
24
25
26
27
28
29
30

31 REFERENCES

- 32 1. Pointer S. Trends in hospitalised injury due to falls in older people, 2007–08 to 2016–17.
33 Injury research and statistics series No 126. Canberra: Australian Institute of Health and
34 Welfare 2019.
- 35 2. Turner N, Jones D, Dawson P, et al. The Perceptions and Rehabilitation Experience of
36 Older People After Falling in the Hospital. *Rehabil Nurs*. 2019;44(3):141-150. doi:
37 10.1097/rnj.000000000000107.
- 38 3. World Health Organization. WHO Global Report on Falls Prevention in Older Age. Geneva:
39 World Health Organization. 2008. Available from: <http://www.who.int/iris/handle/10665/43811>.
40 (accessed 14/03/19)
- 41 4. Kyu HH, Abate D, Abate KH, et al. Global, regional, and national disability-adjusted life-
42 years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195
43 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease
44 Study 2017. *Lancet* 2018;392:1859–922.
- 45 5. NHS Improvement. The Incidence and Costs of Inpatient Falls in Hospitals. 2017. Available
46 from: https://improvement.nhs.uk/documents/1471/Falls_report_July2017.v2.pdf. (accessed
47 22/10/19)
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 6. Dhargave P, Sendhilkumar R. Prevalence of Risk Factors For falls among Elderly People
4 Living in Long-Term Care Homes. *Journal of Clinical Gerontology and Geriatrics*.
5 2016;7(3):99-103.[doi:10.1016/j.jcgg.2016.03.004](https://doi.org/10.1016/j.jcgg.2016.03.004)
6
7
- 8 7. Jørgensen TSH, Hansen AH, Sahlberg M, et al. Nationwide time trends and risk factors
9 for in-hospital falls-related major injuries. *Int J Clin Pract*, 2015;69(6):703–709. doi:
10 10.1111/ijcp.12624
11
- 12 8. Najafpour Z, Godarzi Z, Arab M, et al. Risk Factors for Falls in Hospital In-Patients: A
13 Prospective Nested Case Control Study. *Int J Health Policy Manag* 2019;8(5):300–306. doi:
14 10.15171/ijhpm.2019.11
15
- 16 9. Cameron ID, Dyer SM, Panagoda CE, et al. Interventions for preventing falls in older people
17 in care facilities and hospitals. *Cochrane Database of Syst Rev*. 2018;9:Art. No.: CD005465.
18 doi:10.1002/14651858.CD005465.pub4
19
- 20 10. Santesso N, Carrasco-Labra A, Brignardello-Petersen R. Hip Protectors for Preventing
21 Hip Fractures in Older People. *Cochrane Database Syst Rev*.
22 2014;3.[doi:10.1002/14651858.CD001255.pub5](https://doi.org/10.1002/14651858.CD001255.pub5)
23
- 24 11. Laing AC, Robinovitch SN. Low Stiffness Floors Can Attenuate Fall-Related Femoral
25 Impact Forces by up to 50% without Substantially Impairing Balance in Older Women. *Accid*
26 *Anal Prev*. 2009;41(3):642-50.[doi:10.1016/j.aap.2009.03.001](https://doi.org/10.1016/j.aap.2009.03.001)
27
- 28 12. Redfern MS, Moore PL, Yarsky CM. The Influence of Flooring on Standing Balance
29 among Older Persons. *Hum Factors*. 1997;39(3):445-55.[doi:10.1518/001872097778827043](https://doi.org/10.1518/001872097778827043)
30
- 31 13. Glinka MN, Cheema KP, Robinovitch SN, et al. Quantification of the Trade-Off between
32 Force Attenuation and Balance Impairment in the Design of Compliant Safety Floors. *J Appl*
33 *Biomech*. 2013;29(5):563-72.[doi:10.1123/jab.29.5.563](https://doi.org/10.1123/jab.29.5.563)
34
- 35 14. Beach R, Jackson K, Bigelow KE, editors. Effect of Compliant Flooring on Postural
36 Stability in an Older Adult Population. Proceedings of the 37th Annual Conference of the
37 American Society of Biomechanics; 2013; Omaha, Nebraska, USA.
38
- 39 15. Stephens JM, Goldie PA. Walking Speed on Parquetry and Carpet after Stroke: Effect
40 of Surface and Retest Reliability. *Clin Rehabil*. 1999;13(2):171-
41 81.[doi:10.1191/026921599668553798](https://doi.org/10.1191/026921599668553798)
42
- 43 16. Drahota AK, Ward D, Udell JE, et al. Pilot Cluster Randomised Controlled Trial of
44 Flooring to Reduce Injuries from Falls in Wards for Older People. *Age Ageing*. 2013;42(5):633-
45 40.[doi:10.1093/ageing/aft067](https://doi.org/10.1093/ageing/aft067)
46
- 47 17. Lachance CC, Jurkowski MP, Dymarz AC, et al. Compliant Flooring to Prevent Fall-
48 Related Injuries in Older Adults: A Scoping Review of Biomechanical Efficacy, Clinical
49 Effectiveness, Cost-Effectiveness, and Workplace Safety. *Plos One*.
50 2017;12(2):23.[doi:10.1371/journal.pone.0171652](https://doi.org/10.1371/journal.pone.0171652)
51
52
53
54
55
56
57
58
59
60

18. Donald IP, Pitt K, Armstrong E, et al. Preventing Falls on an Elderly Care Rehabilitation Ward. *Clin Rehabil*. 2000;14(2):178-85.[doi:10.1191/026921500677888641](https://doi.org/10.1191/026921500677888641)
19. Gustavsson J, Bonander C, Andersson R, et al. Investigating the Fall-Injury Reducing Effect of Impact Absorbing Flooring among Female Nursing Home Residents: Initial Results. *Inj Prev*. 2015;21(5):320-4.[doi:10.1136/injuryprev-2014-041468](https://doi.org/10.1136/injuryprev-2014-041468)
20. Hanger HC, Hurley K, Hurring S, White A, editor Low Impact Flooring - Is It Practical in a Hospital? Proceedings of the 6th Biennial Australia and New Zealand Falls Prevention Conference; 2014; Sydney, Australia.
21. Healey F. Does Flooring Type Affect Risk of Injury in Older in-Patients? *Nurs Times*. 1994;90(27):40-1.<https://www.ncbi.nlm.nih.gov/pubmed/8047456>
22. Knoefel F, Patrick L, Taylor J, et al. Dual-Stiffness Flooring: Can It Reduce Fracture Rates Associated with Falls? *J Am Med Dir Assoc*. 2013;14(4):303-5.[doi:10.1016/j.jamda.2012.12.077](https://doi.org/10.1016/j.jamda.2012.12.077)
23. Simpson AH, Lamb S, Roberts PJ, et al. Does the Type of Flooring Affect the Risk of Hip Fracture? *Age Ageing*. 2004;33(3):242-6.[doi:10.1093/ageing/afh071](https://doi.org/10.1093/ageing/afh071)
24. Warren CJ, Hanger HC. Fall and Fracture Rates Following a Change from Carpet to Vinyl Floor Coverings in a Geriatric Rehabilitation Hospital. A Longitudinal, Observational Study. *Clin Rehabil*. 2013;27(3):258-63.[doi:10.1177/0269215512455530](https://doi.org/10.1177/0269215512455530)
25. Yarme J, Yarme H. Flooring and Safety. *Nursing Homes: Long Term Care Management*. 2001;50(10):82.
26. Lachance CC, Feldman F, Laing AC, et al. Study Protocol for the Flooring for Injury Prevention (Flip) Study: A Randomised Controlled Trial in Long-Term Care. *Inj. Prev*. 2016;22(6):453-60.[doi:10.1136/injuryprev-2016-042008](https://doi.org/10.1136/injuryprev-2016-042008)
27. Hanger HC. Low-Impact Flooring: Does It Reduce Fall-Related Injuries? *J Am Med Dir Assoc*. 2017;18(7):588-91.[doi:10.1016/j.jamda.2017.01.012](https://doi.org/10.1016/j.jamda.2017.01.012)
28. Gustavsson J, Bonander C, Nilson F. A Quasi-Experimental Evaluation of Compliant Flooring in a Residential Care Setting. *Plos One*. 2018;13(7).[doi:10.1371/journal.pone.0201290](https://doi.org/10.1371/journal.pone.0201290)
29. Gustavsson J, Rahm G, Jernbro C, et al. Effects of Impact-Absorbing Flooring in Residential Care from the Perspectives of Enrolled Nurses. *Journal of Housing for the Elderly*. 2017;31(4):367-81.[doi:10.1080/02763893.2017.1335670](https://doi.org/10.1080/02763893.2017.1335670)
30. Gustavsson J, Jernbro C, Nilson F. There Is More to Life Than Risk Avoidance - Elderly People's Experiences of Falls, Fall-Injuries and Compliant Flooring. *Int J Qual Stud Health Well-being*. 2018;13(1).[doi:10.1080/17482631.2018.1479586](https://doi.org/10.1080/17482631.2018.1479586)
31. Lachance CC, Zaborska VO, Leung PM, et al. Perceptions About Compliant Flooring from Senior Managers in Lony-Terin Care. *Journal of Housing for the Elderly*. 2018;32(2):194-210.[doi:10.1080/02763893.2018.1431584](https://doi.org/10.1080/02763893.2018.1431584)

- 1
2
3 32. Drahota A, Keenan B, Lachance C, et al. The SAFEST Review: The Shock-Absorbing
4 Flooring Effectiveness SysTematic Review including older adults and staff in care settings.
5 17/148 HTA Researcher-led Evidence Synthesis. HTA - 17/148/11.2019. Available from:
6 <https://www.journalslibrary.nihr.ac.uk/programmes/hta/1714811/#/>. (accessed 14/03/19)
7
8 33. Drahota A, Bell M, Farrell-Savage K, et al. The SAFEST Review: The Shock-Absorbing
9 Flooring Effectiveness SysTematic Review including older adults and staff in care settings.
10 PROSPERO 2019. CRD42019118834. Available from:
11 http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42019118834.
12 (accessed 14/03/19)
13
14 34. Moher D, Shamseer L, Clarke M, et al. *Preferred reporting items for systematic review and*
15 *meta-analysis protocols (PRISMA-P) 2015 statement* . Syst Rev 2015;4:1.doi:10.1186/2046-
16 4053-4-1
17
18 35. Mitnitski A, Howlett SE, Rockwood K. Heterogeneity of Human Aging and Its
19 Assessment. *J Gerontol A Biol Sci Med Sci*. 2017;72(7):877-84.doi:10.1093/gerona/glw089
20
21 36. Ward D, Drahota A, Gal D, et al. Care Home Versus Hospital and Own Home
22 Environments for Rehabilitation of Older People. *Cochrane Database Syst Rev*.
23 2008(4):CD003164.doi:10.1002/14651858.CD003164.pub2
24
25 37. Higgins JPT, Thomas J, Chandler J, et al., editors. *Cochrane Handbook for Systematic*
26 *Reviews of Interventions* Version 6.0 (updated July 2019). Cochrane, 2019. Available from
27 www.training.cochrane.org/handbook.
28
29 38. Birge SJ. Osteoporosis and Hip Fracture. *Clin Geriatr Med*. 1993;9(1):69-86.
30 <https://www.ncbi.nlm.nih.gov/pubmed/8443741>
31
32 39. Brawley EC. Environment- a Silent Partner in Caregiving. In: Kaplan, M, Hoffman, SB,
33 editors. *Behaviors in Dementia: Best Practices for Successful Management: Health*
34 *Professions Press*; 1998. p. 107-24.
35
36 40. Canadian Agency for Drugs and Technologies in Health. Rubberized Flooring in Long
37 Term Care: Clinical Effectiveness and Cost-Effectiveness. Rapid Response Report: Summary
38 of Abstracts.2010. Available from:
39 https://cadth.ca/sites/default/files/pdf/K0269_Rubber_Flooring_in_LTC_final.pdf. (accessed
40 14/03/19)
41
42 41. Center for Healthcare Environmental Management. Proper Flooring: A Critical Measure
43 for Preventing Slips and Falls. *Healthc Hazard Manage Monit*. 2003;16(10):1-5,
44 <https://www.ncbi.nlm.nih.gov/pubmed/12817401>
45
46 42. Cummings SR, Melton LJ. Epidemiology and Outcomes of Osteoporotic Fractures.
47 *Lancet*. 2002;359(9319):1761-7.doi:10.1016/S0140-6736(02)08657-9
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 43. Hester AL. Preventing Injuries from Patient Falls. *American Nurse Today*. 2015;10(7):9-
4 12.
5
6 44. Tibbitts GM. Patients Who Fall: How to Predict and Prevent Injuries. *Geriatrics*.
7 1996;51(9):24-8, 31. <https://www.ncbi.nlm.nih.gov/pubmed/8814111>
8
9 45. Tideiksaar R. Mechanisms of Falls in Community Residing Older Persons. *Pride Institute*
10 *journal of long term home health care*. 1993.
11
12 46. Tideiksaar R, Fletcher B. Keeping Elderly on Their Feet. *Issues in Science and*
13 *Technology*. 1989;5(3):78-81.
14
15 47. Hales M, Johnson JD, Asbury G, et al. Influence of Floor Covering Composition on Force
16 Attenuation During Falls, Wheelchair Mobility, and Slip Resistance. *AATCC REV*. 2015;15:44–
17 53.[doi:10.14504/ar.15.6.4](https://doi.org/10.14504/ar.15.6.4)
18
19 48. Lange B. The Impact of Absorbent Floor in Reducing Hip Fractures: A Cost-Utility
20 Analysis among Institutionalized Elderly: Karlstad University; 2012.
21
22 49. Latimer N, Dixon S, Drahota AK, et al. Cost--Utility Analysis of a Shock-Absorbing Floor
23 Intervention to Prevent Injuries from Falls in Hospital Wards for Older People. *Age Ageing*.
24 2013;42(5):641-5.[doi:10.1093/ageing/af076](https://doi.org/10.1093/ageing/af076)
25
26 50. Njogu F, Brown P. Cost Effectiveness of Impact Absorbent Flooring in Reducing
27 Fractures among Institutionalized Elderly.2008. Available from:
28 [https://mafiadoc.com/queue/cost-effectiveness-of-impact-absorbent-flooring-in-](https://mafiadoc.com/queue/cost-effectiveness-of-impact-absorbent-flooring-in-5ba9567f097c47fb4e8b45e5.html)
29 [5ba9567f097c47fb4e8b45e5.html](https://mafiadoc.com/queue/cost-effectiveness-of-impact-absorbent-flooring-in-5ba9567f097c47fb4e8b45e5.html).
30
31 51. Ryen L, Svensson M. Modelling the Cost-Effectiveness of Impact-Absorbing Flooring in
32 Swedish Residential Care Facilities. *Eur J Public Health*. 2016;26(3):407-
33 11.[doi:10.1093/eurpub/ckv197](https://doi.org/10.1093/eurpub/ckv197).
34
35 52. Soangra R, Jones B, Lockhart TE, editors. Effects of Anti-Fatigue Flooring on Gait
36 Parameters. Proceedings of the 54th Annual Meeting of the Human Factors and Ergonomics
37 Society; 2010; San Francisco, California, USA: SAGE Publications.
38
39 53. Zacker C, Shea D. An Economic Evaluation of Energy-Absorbing Flooring to Prevent
40 Hip Fractures. *Int J Technol Assess Health Care*. 1998;14(3):446-57,
41 <https://www.ncbi.nlm.nih.gov/pubmed/9780531>
42
43 54. Covidence systematic review software. Veritas Health Innovation. Melbourne,
44 Australia: Available at www.covidence.org.
45
46 55. Moher D, Liberati A, Tetzlaff J, et al. Preferred Reporting Items for Systematic Reviews
47 and Meta-Analyses: The Prisma Statement. *PLoS Med*.
48 2009;6(7):e1000097.[doi:10.1371/journal.pmed.1000097](https://doi.org/10.1371/journal.pmed.1000097)
49
50 56. Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic
51 Cochrane Centre, The *The Cochrane Collaboration*. 2014.
52
53
54
55
56
57
58
59
60

- 1
2
3 57. Schünemann H, Brożek J, Guyatt G, et al., editors. Grade Handbook for Grading Quality
4 of Evidence and Strength of Recommendations. Updated October 2013. The GRADE Working
5 Group, editor. Introduction to Grade Handbook. 2013.
6
7
8 58. GRADEpro GDT. Gradepro Guideline Development Tool [Software]. McMaster
9 University, 2015 (developed by Evidence Prime, Inc.). Available from gradepr.org. 2015.
10
11 59. Lamb SE, Jørstad-Stein EC, Hauer K, et al. Development of a Common Outcome Data
12 Set for Fall Injury Prevention Trials: The Prevention of Falls Network Europe Consensus. *J*
13 *Am Geriatr Soc*. 2005;53(9):1618-22. [doi:10.1111/j.1532-5415.2005.53455.x](https://doi.org/10.1111/j.1532-5415.2005.53455.x)
14
15
16 60. Cameron ID, Robinovitch S, Birge S, et al. Hip Protectors: Recommendations for
17 Conducting Clinical Trials--an International Consensus Statement (Part II). *Osteoporos Int*.
18 2010;21(1):1-10. [doi:10.1007/s00198-009-1055-2](https://doi.org/10.1007/s00198-009-1055-2)
19
20
21 61. Lachance CC, Mackey DC. Feasibility of Compliant Flooring in Long-Term Care: Results
22 from a Stakeholder Symposium. *Can J Aging*. 2018;37(1):84-
23 94. [doi:10.1017/S0714980817000551](https://doi.org/10.1017/S0714980817000551)
24
25
26 62. Higgins JPT, Sterne JAC, Savović J, et al. A Revised Tool for Assessing Risk of Bias in
27 Randomized Trials. In: Chandler J, McKenzie J, Boutron I, Welch V, editors. Cochrane
28 Methods. *Cochrane Database of Systematic Reviews*. 10 (Suppl 1)2016.
29
30
31 63. Sterne JA, Hernán MA, Reeves BC, et al. Robins-I: A Tool for Assessing Risk of Bias in
32 Non-Randomised Studies of Interventions. *BMJ*. 2016;355:i4919. [doi:10.1136/bmj.i4919](https://doi.org/10.1136/bmj.i4919)
33
34
35 64. Aromataris E, Munn Z, editors. Joanna Briggs Institute Reviewer's Manual.: The Joanna
36 Briggs Institute. Available from <https://reviewersmanual.joannabriggs.org/>; 2017.
37
38
39 65. Soilemezi D, Drahota A, Crossland J, et al. The Role of the Home Environment in
40 Dementia Care and Support: Systematic Review of Qualitative Research. *Dementia (London)*.
41 2017. [doi:10.1177/1471301217692130](https://doi.org/10.1177/1471301217692130)
42
43
44 66. Garrison KR, Shemilt I, Donell S, et al. Bone Morphogenetic Protein (Bmp) for Fracture
45 Healing in Adults. *Cochrane Database Syst Rev*.
46 2010(6):CD006950. [doi:10.1002/14651858.CD006950.pub2](https://doi.org/10.1002/14651858.CD006950.pub2)
47
48
49 67. Drummond MF, Jefferson TO. Guidelines for Authors and Peer Reviewers of Economic
50 Submissions to the BMJ. The Bmj Economic Evaluation Working Party. *BMJ*.
51 1996;313(7052):275-83,
52
53
54 68. Philips Z, Bojke L, Sculpher M, et al. Good Practice Guidelines for Decision-Analytic
55 Modelling in Health Technology Assessment: A Review and Consolidation of Quality
56 Assessment. *Pharmacoeconomics*. 2006;24(4):355-71. [doi:10.2165/00019053-200624040-00006](https://doi.org/10.2165/00019053-200624040-00006)
57
58
59 69. The GRADE-CERQual Project Group. How to Use and Interpret Findings from
60 Qualitative Evidence Syntheses Assessed Using the Cerqual Approach: A Practical Guide for

1
2
3 Decision Makers in Health and Social Care and Other Users.2018. Available from:
4 <https://www.cerqual.org/>. (accessed 13/03/19)
5

6 70. Lewin S, Booth A, Glenton C, et al. Applying Grade-Cerqual to Qualitative Evidence
7 Synthesis Findings: Introduction to the Series. *Implement Sci.* 2018;13(Suppl
8 1):2.[doi:10.1186/s13012-017-0688-3](https://doi.org/10.1186/s13012-017-0688-3)
9

10 11 71. Wager E, Wiffen PJ. Ethical Issues in Preparing and Publishing Systematic Reviews. *J*
12 *Evid Based Med.* 2011;4(2):130-4.[doi:10.1111/j.1756-5391.2011.01122.x](https://doi.org/10.1111/j.1756-5391.2011.01122.x)
13

14 72. Graham ID, Logan J, Harrison MB, et al. Lost in Knowledge Translation: Time for a Map?
15 *J Contin Educ Health Prof.* 2006;26(1):13-24.[doi:10.1002/chp.47](https://doi.org/10.1002/chp.47)
16
17
18
19

20 **AUTHOR STATEMENT**

21
22 AD is Principal Investigator (guarantor) of the project, and was involved in the project
23 conception and design, and drafting of the protocol. BK, CL, AL, and DM were all involved in
24 the conception and design of the project, and revising the protocol content. JR contributed to
25 the design of the health economics component and revising the protocol. LF contributed to the
26 design of the Summary of Findings Tables component, and drafting of this manuscript. AD,
27 BK, CL, and JR were co-applicants on the original funding proposal to HTA. All authors are
28 also Advisory Board members and have read and approved the manuscript.
29
30
31
32
33
34
35

36 **ACKNOWLEDGEMENTS**

37 We would like to thank our public involvement members, Mrs Margaret Bell, Mrs Elizabeth
38 Burden, and Mrs Joleen Tobias, and further members of our Advisory Board: Nadra Ahmed
39 (National Care Association), Alison Cracknell (Leeds Teaching Hospitals NHS Trust), Kirsten
40 Farrell-Savage (University of Portsmouth), Olanrewaju Okunribido (Health & Safety
41 Executive), Jonathan Stewart (Health Estates and Facilities Management Association), Julie
42 Windsor (NHS Improvement), and Anna Winfield (Leeds Teaching Hospitals NHS Trust). Our
43 Advisory Board members have provided feedback and advice throughout the funding
44 application process and when designing the protocol, and have approved the protocol. OO
45 was also a co-applicant on the original funding proposal to HTA.
46
47
48
49
50
51
52
53

54 **FUNDING STATEMENT**

55 This report is independent research funded by the National Institute for Health Research
56 (NIHR Health Technology Assessment, 17/148/11 – The SAFEST Review: The Shock-
57 Absorbing Flooring Effectiveness SysTematic Review including older adults and staff in care
58
59
60

1
2
3 settings). The views expressed in this publication are those of the authors and not necessarily
4 those of the NHS, the National Institute for Health Research or the Department of Health and
5 Social Care. The Health & Safety Executive are supporting 10 days of Olanrewaju
6 Okunribido's time in kind on this project.
7
8
9

10 11 **COMPETING INTERESTS STATEMENT** 12

13 AD, CL, AL, and DM have undertaken studies that will be a part of this review.
14

15
16 AD and BK have been collaborating with members of the Health & Safety Laboratory (2018-
17 present) on some unfunded academic research using a new testing procedure to assess the
18 shock-absorbency of various floor coverings. Five flooring manufacturers delivered free
19 samples to use in the project. AD and BK have no stake in any of these companies.
20
21
22

23
24 In 2015, AD was involved in a collaborative funding application with Polyflor for some SBRI
25 Healthcare innovation funding. The application was short-listed but unsuccessful. AD has no
26 stake in this company.
27
28
29

30 AL reports grants from SofSurfaces Inc, grants and personal fees from SorbaShock LLC,
31 grants and personal fees from Viconic Sporting, outside the submitted work. AL is a member
32 of an ASTM Work Group (WK38804) whose Technical Contact is the President of SATech.
33 SATech has donated flooring materials to AL's laboratory that have formed the basis of several
34 studies examining the biomechanical effectiveness of compliant flooring (i.e. safety flooring).
35 He has never had (nor does he currently have) any financial links to the company.
36
37
38
39
40

41 CL is employed at the Canadian Agency for Drugs and Technologies in Health (CADTH).
42
43

44 JR is a member of the NIHR's HTA/EME editorial board (0.1 wte).
45
46


47 LF has nothing to disclose.
48
49

50 51 **Additional Files** 52

53 Supplementary file 1. PRISMA-P checklist.

54 Supplementary file 2. Medline search strategy

55
56 Figure 1. Theoretical framework of potential effect modifiers.
57
58
59
60



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

PRISMA- P 2015 Checklist

This checklist has been adapted from the operationalized checklist available from: <http://www.prisma-statement.org/Extensions/Protocols.aspx> which is based on Table 3 in Moher et al. Syst Rev. 2015;4(1):1. doi: 10.1186/2046-4053-4-1

Section/topic	#	Checklist item	Information reported		Page number(s)
			Yes	No	
ADMINISTRATIVE INFORMATION					
Title					
Identification	1a	Identify the report as a protocol of a systematic review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	<input type="checkbox"/>	<input checked="" type="checkbox"/>	n/a
Registration	2	If registered, provide the name of the registry (e.g., PROSPERO) and registration number in the Abstract	<input checked="" type="checkbox"/>	<input type="checkbox"/>	2
Authors					
Contact	3a	Provide name, institutional affiliation, and e-mail address of all protocol authors; provide physical mailing address of corresponding author	<input checked="" type="checkbox"/>	<input type="checkbox"/>	1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	22
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	<input checked="" type="checkbox"/>	<input type="checkbox"/>	5
Support					
Sources	5a	Indicate sources of financial or other support for the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	22
Sponsor	5b	Provide name for the review funder and/or sponsor	<input checked="" type="checkbox"/>	<input type="checkbox"/>	22
Role of sponsor/funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	<input checked="" type="checkbox"/>	<input type="checkbox"/>	22
INTRODUCTION					
Rationale	6	Describe the rationale for the review in the context of what is already known	<input checked="" type="checkbox"/>	<input type="checkbox"/>	4
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	5
METHODS					

Section/topic	#	Checklist item	Information reported		Page number(s)
			Yes	No	
Eligibility criteria	8	Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	5-7
Information sources	9	Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage	<input checked="" type="checkbox"/>	<input type="checkbox"/>	7-8
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Supplementary file 2
STUDY RECORDS					
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	8
Selection process	11b	State the process that will be used for selecting studies (e.g., two independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	9
Data collection process	11c	Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	<input checked="" type="checkbox"/>	<input type="checkbox"/>	9,11
Data items	12	List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications	<input checked="" type="checkbox"/>	<input type="checkbox"/>	9
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	<input checked="" type="checkbox"/>	<input type="checkbox"/>	9,10
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	<input checked="" type="checkbox"/>	<input type="checkbox"/>	10 (quantitative), 12 (qualitative)
DATA					
Synthesis	15a	Describe criteria under which study data will be quantitatively synthesized	<input checked="" type="checkbox"/>	<input type="checkbox"/>	11-12
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data, and methods of combining data from studies, including any planned exploration of consistency (e.g., I^2 , Kendall's tau)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	11-12
	15c	Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, meta-regression)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	12
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	<input checked="" type="checkbox"/>	<input type="checkbox"/>	12, 13
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective reporting within studies)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	10, 11

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Section/topic	#	Checklist item	Information reported		Page number(s)
			Yes	No	
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (e.g., GRADE)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	13,14

For peer review only

Medline search strategy

Search line	Terms
1	MH "Wounds and Injuries+"
2	MH "Accidental Falls/PC"
3	MH "Hip Fractures+/PC"
4	falls
5	faller\$
6	S1 OR S2 OR S3 OR S4 OR S5
7	MH "Aged+"
8	MH "Middle Aged"
9	Older
10	Senior\$
11	elderly
12	S7 OR S8 OR S9 OR S10 OR S11
13	S6 AND S12
14	MH "Residential Facilities+"
15	MH "Long-Term Care"
16	MH "Institutionalization"
17	MH "Hospitalization"
18	MH "Subacute Care"
19	MH "Hospitals+"
20	MH "Hospital Units"
21	MH "Rehabilitation Centers"
22	MH "Inpatients"
23	MH "Geriatric Assessment"
24	("long stay" or "long term" or "acute" or "sub-acute" or "subacute" or "residential" or "hospital") N3 (care or ward# or hospital)
25	(rehabilitation or geriatric) N1 (ward# or hospital# or unit# or department#)
26	hostel\$ or nursing home\$
27	inpatient
28	resident\$
29	institution\$
30	S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29
31	S13 and S30
32	floor* NOT (pelvic floor OR sinus OR mouth)
33	carpet*
34	ground surface\$
35	smartcell*
36	tarkett
37	softile
38	sorbashock
39	forbo
40	kradal
41	noraplan
42	MH "Floors and Floorcoverings"
43	S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42
44	S31 AND S43
45	MH "Animals+"
46	MH "Humans"
47	S45 NOT S46
48	S44 NOT S47
49	S44 NOT S47 Limiters - Date of Publication: 20160501-